



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 10 2004

Signature: Kari Alitalo

Attorney Docket No.: 28967/34891A  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: Alitalo et al.

Application No.: 09/765,534

Confirmation No.: 1420

Filed: January 19, 2001

Art Unit: 1646

For: Flt4 (VEGFR-3) as a Target for Tumor Imaging  
and Anti-Tumor Therapy

Examiner: Murphy, Joseph F.

**DECLARATION OF KARI ALITALO, PURSUANT TO 37 C.F.R. § 1.132**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Kari Alitalo, do hereby declare and state as follows:

**DECLARANT BACKGROUND**

1. I am one of the inventors of the subject matter claimed in U.S. Patent Application No. 09/765,534 (referred to herein as "the patent application") [and all parent applications, e.g., U.S.S.N. 07/959,951, filed October 9, 1992].

2. I am presently a Research Professor with The Finnish Medical Research Council of the Finnish Academy of Sciences. Since receiving my M.D. and M.Sc.D. in 1977 and 1980, respectively, from the University of Helsinki, I have worked substantially continuously as a professor and scientific researcher in Finland in areas of cellular and molecular biology and cancer research. My research has included substantial studies and explorations in fields of cancer, cancer metastasis, angiogenesis, and lymphangiogenesis. Through this research, I have gained extensive experience working with recombinant DNA/protein expression, analysis, and manipulation both *in vitro* and *in vivo*. My experience includes making and using antibodies raised against protein antigens.

3. In addition to my own research efforts and my collaborations with others, I receive numerous invitations to speak at national and international symposiums in

these areas of study, I supervise post-graduate research of others, I have authored and co-authored numerous original research articles published in peer-reviewed journals, and I have served on the editorial board of such journals. My *curriculum vitae* is attached hereto as Exhibit 1.

4. As shown in my *curriculum vitae*, I also have conducted and collaborated in substantial research relating to the Flt4 receptor tyrosine kinase, also known as "Vascular Endothelial Growth Factor Receptor-3" or "VEGFR-3." This receptor is a member of a subfamily of class III tyrosine kinase receptors that also includes VEGFR-1 (also known as Flt1) and VEGFR-2 (also known as KDR). The human Flt4 receptor has at least two sequences a "short" form (SEQ ID NO: 2) and "long" form (SEQ ID NO: 4), differing in their C-terminal region, but having the same extracellular domain. "Vascular Endothelial Growth Factor C" or "VEGF-C" acts as a high affinity ligand for the VEGFR-3 receptor, binding and stimulating phosphorylation of VEGFR-3. I have co-authored publications and filed patent applications relating to Flt4/VEGFR-3. Thus, my laboratory, my collaborators, and I have substantial expertise and experience working with and expressing the Flt4 receptor, fragments of that receptor, and antibodies specific for the same.

#### DISCUSSION OF CLAIMED SUBJECT MATTER

5. I understand that we are claiming in the patent application an isolated peptide or protein comprising a member selected from the group consisting of:

(a) the Flt4 receptor tyrosine kinase (Flt4) extracellular domain amino acid sequence set forth in SEQ ID NO: 2 or 4 and;

(b) a fragment of said extracellular domain, wherein the fragment includes sufficient amino acid sequence of SEQ ID NO: 2 or 4 to generate an immune response in a nonhuman mammal to produce antibodies that specifically bind to Flt4 (SEQ ID NO: 2 or 4). Before 1992 and today, scientists in my field understood the term "specifically binds" to refer to antibodies that immunoreact with one antigen (*e.g.*, Flt4) and fail to appreciably cross-react with other known, related antigens (such as the Flt1 and KDR sequences that were known at the time we filed the first priority application in 1992). Anti-Flt4 antibodies and uses thereof are described in the patent application. *See, e.g.*, the specification at top of page 34 and at page 35.

7. I understand that we are claiming peptides that comprise fragments of the Flt4 amino acid sequence (SEQ ID NO: 4) defined by cyanogen bromide (CNBr) cleavage sites that exist in the Flt4 sequence; specifically, we are claiming fragments that contain some sequence from the extracellular domain of Flt4. The patent application describes CNBr cleavage of Flt4 at page 32, lines 9-14. CNBr cleaves polypeptides at the C-terminal end of methionine residues. *See, e.g.*, Exhibit C, Stryer page 55; Exhibit B, Sambrook, page 17.29. The Flt4 peptides defined by CNBr cleavage sites and that contain extracellular domain amino acids are shown in Exhibit D.

#### INFORMATION RELEVANT TO THE ENABLEMENT REJECTION

8. I understand that the Patent Office has rejected certain claims in the present application, alleging that the patent application does not adequately teach a practitioner with average experience in the field of the invention to make and use the invention in a manner commensurate in scope with the claims. The Patent Office alleged lack of enablement for a Flt4 fragment encoded by 200 nucleotides of SEQ ID NO: 1 or 3, a polypeptide comprising a Flt4 extracellular domain fragment, and a polypeptide comprising Flt4 peptides obtained by CNBr cleavage. I am providing this declaration to provide information relevant to overcoming the rejection.

9. The present application teaches how to make and use not only Flt4 polypeptides, but also fragments and variants thereof. *See, e.g.*, specification at page 32, lines 1-14. By 1992, scientists were able to produce peptides by both chemical synthesis and through *in vitro* and cellular expression systems. *See, e.g.*, Exhibit C, Stryer, pages 66-67, and Exhibit B, Sambrook, chapters 16 and 17. Peptides could also be produced from larger polypeptides/proteins using digestion with various agents, *e.g.*, cyanogen bromide (CNBr) as discussed above.

10. The specification describes Flt4 peptides and their use in producing both polyclonal and monoclonal antibodies, *see, e.g.*, page 25, lines 25-27, and page 33, lines 3-23. Techniques for producing both monoclonal and polyclonal antibodies were well known by 1992. *See generally* Exhibit A, Harlow, and Exhibit B, Sambrook, pages 18.3-18.18. Likewise, techniques to select an antibody that was immunospecific for one protein, and which failed to cross-react with other proteins, were well known. Western blotting provides one way of testing the specificity of a peptide and antibodies that specifically bind to that

peptide. *See, e.g.*, Exhibit C, Stryer, page 63; Exhibit B, Sambrook, pages 18.60-18.61. Other available immunoassays include radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISA). *See, e.g.*, Exhibit B, Sambrook, pages 18.19-18.25 and Exhibit C, Stryer, page 63. Such assays lend themselves to automation, allowing rapid screening of antibodies. It was well known that cross-reactive antibodies could more easily be avoided by immunizing with peptides that had sequence unique to the desired antigens, rather than peptides whose complete sequence was shared by two or more proteins. To identify peptides with unique sequence, a practitioner could have used a sequence alignment between the Flt4 sequence taught in the specification and other known protein sequences. The patent application provides an alignment between VEGFR-1 and Flt4. *See* Figs. 2A-F and at page 24, lines 12-13. One could also make a similar alignment between Flt4 and VEGFR-2 (or what sequence of VEGFR-2 was known in 1992), or a three way alignment between the three family members. Computer software existed in 1992 to permit scientists to generate such alignments rapidly.

#### **INFORMATION RELEVANT TO THE PRIOR ART REJECTION**

11. I also understand that the Patent Office has alleged that some of the claimed subject matter is not novel in view of Terman et al., *Oncogene*, 6: 1677-1683 (1991). I am further providing this declaration to provide information relevant to overcoming that rejection. Some of the claims specify a Flt4 extracellular domain fragment with sufficient Flt4 sequence to generate an immune response that is specific to Flt4. These requirements exclude peptides that consist of perfect sequence identity with the Terman sequence or hypothetical fragments of the Terman KDR sequence. If one immunized a mammal with KDR peptides, one would expect to generate antibodies that would bind KDR specifically. One might also generate antibodies that bound KDR as well as other proteins, *i.e.*, nonspecifically. However, a practitioner could not have produced and cannot produce an antibody that specifically binds Flt4 using only the KDR sequence taught by Terman or any later known KDR sequence, *e.g.*, that used by the Office in its "Sequence Comparison A."

12. Terman also fails to disclose a peptide sequence that matches a Flt4 fragment defined by CNBr cleavage sites and that contains Flt4 extracellular domain sequence. Exhibit D shows Flt4 fragment amino acid sequences with stop/start sites corresponding to positions of cyanogen bromide cleavage of Flt4 receptor tyrosine kinase and

Application No.: 09/765,534

Docket No.: 28967/34891A

comprising at least one extracellular domain amino acid. Exhibit E provides a superposition of the fragments of Exhibit D on the Sequence Comparison A provided with the Office action. This comparison shows that the complete sequence of each of these Flt4 fragments is divergent from (non-identical to) the KDR sequence.

### **BIBLIOGRAPHY**

13. In the above discussion, I have made reference to several publications that were widely known and available to scientists in my field by 1992:

Exhibit A) Harlow, E. et al., "Antibodies: A Laboratory Manual," Cold Spring Harbor Laboratory, 1988 [hereinafter, Harlow].

Exhibit B) Sambrook, J., et al., "Molecular Cloning A Laboratory Manual," 2nd ed., Cold Spring Harbor Laboratory Press, 1989 [hereinafter, Sambrook].

Exhibit C) Stryer, L., Biochemistry, 3rd ed., Freeman, 1988 [hereinafter, Stryer].

Selected, relevant pages from these publications have been provided in the attached Exhibits.

### **OATH/VERIFICATION**

14. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief and believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated:

26.10.04

Signature:

Jan Amel

# Antibodies

## A LABORATORY MANUAL

Ed Harlow  
Cold Spring Harbor Laboratory

David Lane  
Imperial Cancer Research Fund Laboratories



Cold Spring Harbor Laboratory  
1988

EXHIBIT A

# CONTENTS

## Antibodies A LABORATORY MANUAL

All rights reserved.  
© 1988 by Cold Spring Harbor Laboratory  
Printed in the United States of America  
Book and cover design by Emily Harste

Cover: "Nature Abstracted," watercolor by Carl Molno

Library of Congress Cataloging-in-Publication Data

Antibodies : a laboratory manual / by Ed Harlow, David Lane.

p. cm.

Bibliography: p.

Includes index.

ISBN 0-87969-314-2

1. Immunoglobulins--Laboratory manuals. 2. Immunochromatography--Laboratory manuals. I. Harlow, Ed. II. Lane, David (David P.).

1982--

QR186.7.A53 1988

S74.2'93'028--dc19

Researchers using the procedures of this manual do so at their own risk. Cold Spring Harbor Laboratory makes no representations or warranties with respect to the material set forth in this manual and has no liability in connection with the use of these materials.

Certain experimental procedures in this manual may be the subject of national or local legislation or agency restrictions. Users of this manual are responsible for obtaining the relevant permissions, certificates, or licenses in these cases. Neither the authors of this manual nor Cold Spring Harbor Laboratory assume any responsibility for failure of a user to do so.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cold Spring Harbor Laboratory for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$1.00 per article is paid directly to CCC, 27 Congress St., Salem MA 01970. [0-87969-314-2/88 \$1.00 + .00]. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

All Cold Spring Harbor Laboratory publications may be ordered directly from Cold Spring Harbor Laboratory, Box 100, Cold Spring Harbor, New York 11724. Phone: 1-800-843-4388. In New York (516) 367-8423.

Preface xi

1	IMMUNE RESPONSE	1
	A simple review of the immune response... definitions of standard terms... Specific interactions between host proteins and foreign molecules control the strength and effectiveness of an immune response. Selective expansion or deletion of antigen-specific lymphocytes is the cellular basis of the response.	
2	ANTIBODY MOLECULES	7
	Structure of the antibody molecule... generation of a functional immunoglobulin heavy- or light-chain gene... Specific mechanisms have evolved to allow the production of a vast repertoire of antigen recognition sites. This repertoire allows an organism to respond to an extensive array of foreign molecules.	
3	ANTIBODY-ANTIGEN INTERACTIONS	23
	Structure of antibody-antigen interactions... affinity... avidity... Antibodies and antigens are held by a series of noncovalent bonds. The strength of the individual interactions and the overall stability of an antibody-antigen complex determines the ultimate success of every immunochemical test.	
4	ANTIBODY RESPONSE	37
	Molecular and cellular development of an antibody response... multiple steps of a primary or secondary antibody response... The generation of a strong antibody response relies on cell-to-cell communication among B cells, helper T cells, and antigen presenting cells. Manipulating these interactions allows the tailoring of a response to a chosen antigen.	

iii

## 5 IMMUNIZATIONS 53

Many molecules can be used as successful immunogens to raise useful antibodies .... In many cases, even poor immunogens can be altered to produce better responses.

### IMMUNOGENICITY 55

#### SOURCES OF ANTIGEN 59

##### Pure Antigens 60

##### Purifying Antigens from Polyacrylamide Gels 61

##### Locating the Antigen after Electrophoresis 61

##### Processing of the Gel Fragments for Immunization 67

##### Haptens 72

##### Synthetic Peptides 72

##### Designing the Peptide 75

##### Coupling Peptides to Carrier Proteins 78

##### Preparing Antigens from Bacterial Overexpression Vectors 88

#### IMMUNIZING ANIMALS 92

##### Choice of Animal 93

##### Adjuvants 96

##### Dose of the Antigen 100

##### Form of the Antigen 100

##### Routes of Injection 103

##### Subcutaneous Injections 104

##### Intramuscular Injections 106

##### Intradermal Injections 108

##### Intravenous Injections 110

##### Intraperitoneal Injections 112

##### Injections into Lymphoid Organs 112

##### Boosts 114

#### SAMPLING SERUM 116

##### Test Bleeds 116

##### Serum Preparation 119

##### Exsanguination 120

##### Inducing Ascites Fluid in Mice 121

#### MAKING WEAK ANTIGENS STRONG 124

##### Modifying Antigens 124

##### Coupling Antigens 128

##### Immune Complexes as Antigens 135

## 6 MONOCLONAL ANTIBODIES 139

Allelic exclusion ensures that a clonal population of cells arising from an individual B cell will secrete identical antibodies with a unique antigen recognition site. Techniques of cell fusion allow individual B cells to be converted into permanent antibody-secreting cell lines. These monoclonal antibodies can be used to test for the presence of a particular epitope.

#### PRODUCTION OF MONOCLONAL ANTIBODIES 148

##### Stages of Hybridoma Production 148

#### IMMUNIZING MICE 150

##### Dose and Form of the Antigen 151

##### Soluble Proteins 151

##### Particulate Proteins 153

#### Proteins Produced by Overexpression 153

##### Synthetic Peptides 153

##### Live Cells 153

##### Nucleic Acids 154

##### Carbohydrates 154

##### Route of Inoculation 155

##### Identifying Individual Mice 171

##### Test Bleeds 171

##### Deciding to Boost Again or to Fuse 173

#### DEVELOPING THE SCREENING METHOD 174

##### Screening Strategies 175

##### Antibody Capture Assays 175

##### Antigen Capture Assays 188

##### Functional Assays 195

#### PRODUCING HYBRIDOMAS 196

##### Preparation for Fusions 197

##### Drug Selections 203

##### Final Boost 207

##### Preparing the Parental Cells for Fusions 207

##### Fusions 210

##### Feeding Hybridomas 214

##### Screening 216

##### Expanding and Freezing Positive Clones 218

##### Single-Cell Cloning 219

##### Unstable Lines 228

##### Contamination 228

##### Classing and Subclassing of Monoclonal Antibodies 231

##### Selecting Class-Switch Variants 238

#### INTERSPECIES HYBRIDOMAS 240

#### HUMAN HYBRIDOMAS 241

#### FUTURE TRENDS 242

## 7 GROWING HYBRIDOMAS 245

Hybridomas and myelomas can be grown under standard mammalian tissue culture conditions, and monoclonal antibodies can be collected as spent media or following the induction of ascites in animals.

#### GROWING HYBRIDOMAS AND MYELOMAS 247

##### Tissue Culture 247

##### Long-Term Storage of Cell Lines 257

##### Contamination by Bacteria or Fungi 261

##### Contamination by Mycoplasma 265

#### PRODUCING AND STORING MONOCLONAL ANTIBODIES 271

#### DRUG SELECTION 277



**8 STORING AND PURIFYING ANTIBODIES 283**

Antibodies are relatively stable proteins that can be stored easily and purified by a large number of common protein chemistry techniques.

**STORING ANTIBODIES 285****PURIFYING ANTIBODIES 288****Conventional Methods 289****Purification on Protein A Beads 309****Immunoaffinity Purification of Antibodies 312****9 LABELING ANTIBODIES 319**

When purified antibodies are labeled with an easily detectable "tag," they can be used to identify specific antigens even when displayed in a complicated mixture of other molecules.

**Direct Versus Indirect Labeling 321****Choice of Label 321****LABELING ANTIBODIES WITH IODINE 324****Iodinations Using Chemical Oxidation 327****Iodinations Using Enzymatic Oxidation 334****Iodinations Using Bolton-Hunter Reagent 338****LABELING ANTIBODIES WITH BIOTIN 340****LABELING ANTIBODIES WITH ENZYMES 342****Coupling Antibodies to Horseradish Peroxidase 344****Coupling Antibodies to Alkaline Phosphatase 349****Coupling Antibodies to  $\beta$ -Galactosidase 350****LABELING ANTIBODIES WITH FLUOROPHORES 353****LABELING MONOCLONAL ANTIBODIES BY BIOSYNTHESIS 358****10 CELL STAINING 359**

When labeled antibodies are used to stain cells or tissues, they can be used to determine not only the presence of an antigen but also its localization.

**MAJOR CONSTRAINTS 363****CHOICE OF ANTIBODY 364****Cell Staining with Polyclonal Antibodies 364****Cell Staining with Monoclonal Antibodies 365****Cell Staining with Pooled Monoclonal Antibodies 365****PROTOCOLS FOR CELL STAINING 367****Preparation of Cells and Tissues 367****Adherent Cells 367****Suspension Cells 370****Yeast Cells 374****Tissue Sections 376****Fixation 384****Attached Cells 385****Suspension Cells 388****Yeast Cells 389****Antibody Binding 390****Detection 396****Detecting Enzyme-Labeled Reagents 400****Detecting Fluorochrome-Labeled Reagents 409****Detecting Gold-Labeled Reagents 412****Detecting Iodine-Labeled Reagents 414****Mounting 416****Photographing the Samples 419****11 IMMUNOPRECIPITATION 421**

Antibody-antigen complexes can be purified by collection on matrices that specifically bind antibodies. This is a versatile technique for determining many properties of soluble antigens.

**MAJOR CONSTRAINTS 424****CHOICE OF ANTIBODY 425****Immunoprecipitations Using Polyclonal Antibodies 425****Immunoprecipitations Using Monoclonal Antibodies 426****Immunoprecipitations Using Pooled Monoclonal Antibodies 427****IMMUNOPRECIPITATION PROTOCOLS 429****Labeling Protein Antigens 429****Labeling Cells in Tissue Culture 430****Labeling Yeast Cells 438****Labeling Bacteria 442****Isolating Immunoprecipitated Proteins 445****Lysing Cells 446****Lysis of Tissue Culture Cells 448****Lysis of Yeast Cells 452****Lysis of Bacteria 457****Denaturing Lysis 460****Preclearing the Lysate 461****Forming the Immune Complexes 464****Purifying the Immune Complexes 466****12 IMMUNOBLOTTING 471**

Many antigens are easiest to study on immunoblots. Because the antigens are resolved prior to immunochemical detection, antibody binding is not limited to soluble molecules and can be used to detect and quantitate antigens from a wide variety of sources.

**MAJOR CONSTRAINTS 474****CHOICE OF ANTIBODY 475****Immunoblots Using Polyclonal Antibodies 475****Immunoblots Using Monoclonal Antibodies 476****Immunoblots Using Pooled Monoclonal Antibodies 477****IMMUNOBLOTTING PROTOCOLS 479****Sample Preparation 480****Gel Electrophoresis 484****Transfer of Proteins from Gels to Membranes 486****Staining the Blot for Total Protein (Optional) 493****Blocking Nonspecific Binding Sites on the Blot 497**

## 15 REAGENTS 613

## BACTERIAL CELL WALL PROTEINS THAT BIND ANTIBODIES 615

Protein A 616

Preparing *S. aureus* for Collecting Immune Complexes 620

Protein G 622

## ANTI-IMMUNOGLOBULIN ANTIBODIES 622

Preparing Anti-Immunoglobulin Antibodies 624

Proteolytic Fragments of Antibodies 626

## ADSORPTION TO REMOVE NONSPECIFIC BINDING 632

Preparing Acetone Powders 633

Appendix I Electrophoresis 635

Appendix II Protein Techniques 658

Appendix III General Information 682

Appendix IV Bacterial Expression 690

References 697

Index 711

## Addition of Antibody 499

## Detection 502

Detection with Radiolabeled Reagents 503

Detection with Enzyme-Labeled Reagents 504

## 13 IMMUNOAFFINITY PURIFICATION 541

When antibodies are covalently attached to a solid matrix, they can be used to purify large amounts of a particular antigen. Because of the specificity of the antibody-antigen interaction, these techniques provide excellent results, exceeding all other single-column methods in yield and purity.

## MAJOR CONSTRAINTS 544

## CHOICE OF ANTIBODY 546

Immunoaffinity Purification Using Polyclonal Antibodies 546

Immunoaffinity Purification Using Monoclonal Antibodies 547

Immunoaffinity Purification Using Pooled Monoclonal Antibodies 547

## PROTOCOLS FOR IMMUNOAFFINITY PURIFICATION 549

Preparing Antibody Affinity Columns 549

Coupling Antibodies to Protein A Beads 521

Coupling Antibodies to Activated Beads 528

Preparing Antibody-Affinity Columns with Activated Antibodies 538

Binding Antigens to Immunoaffinity Columns 541

Eluting Antigens from Immunoaffinity Columns 547

Eluting the Antigen 550

Strategies for Testing Elution Conditions 551

## 14 IMMUNOASSAY 553

A wide variety of immunoassays can be used to detect and quantitate antigens and antibodies, often well beyond the sensitivity of conventional methods. These assays are particularly useful when a large number of samples need to be analyzed or when extreme sensitivity is required.

## TYPES OF IMMUNOASSAYS 555

## DECIDING WHERE TO START 557

Detecting and Quantitating Antigens 559

Detecting and Quantitating Antibodies 560

## PROTOCOLS FOR IMMUNOASSAYS 561

Antibody Capture Assays 563

Two-Antibody Sandwich Assays 579

Antigen Capture Assays 585

Detection 591

Iodine-Labeled Antigens, Antibodies, or Secondary Reagents 591

Biotin-Labeled Antibodies, Antigens, or Secondary Reagents 591

Enzyme-Labeled Antigens, Antibodies, or Secondary Reagents 592

## DESIGNING IMMUNOASSAYS 599

Assay Geometry 600

Solid-Phase Matrices for Immunoassays 605

Alternative Detection Methods 612

The major problem that is encountered when preparing anti-peptide antibodies is whether they will recognize the native protein. Assays that need or benefit from anti-native antibodies, such as immunoprecipitation, many cell staining techniques, or immunoaffinity purification, will succeed only when the peptide sequence is displayed on the surface of the native molecule in a conformation similar to the peptide-carrier conjugate. Therefore, the successful production of anti-peptide antibodies is often determined by the researcher's ability to predict the location of certain peptide sequences in the three-dimensional structure of the protein.

Because of their size, peptides may not be immunogenic on their own. To elicit an antibody response directly, they must contain all of the features of any immunogen, notably they must have an epitope for B-cell binding and a site for class II-T-cell receptor binding. Some peptides, even surprisingly small ones, contain both these sites (or more properly, one sequence that can serve both functions), and these peptides can be used without carriers (e.g., see Beachy et al. 1981; Lerner et al. 1981; Dreesman 1982; Jackson 1982; Atassi and Webster 1983; Young et al. 1983). Unfortunately, there are no methods, short of immunization, to test this, and therefore, most peptides are coupled to carrier proteins before injection. An exciting recent development is the use of synthetic class II-T-cell receptor sites synthesized directly with the desired epitope (Francis et al. 1987; see also, Good et al. 1987; Borrás-Cuesta et al. 1987; Leclerc et al. 1987). Although there are not enough cases to determine how widely applicable this approach will be, the concept is provocative. With this strategy, the peptide of interest is synthesized as either an amino- or carboxy-terminal extension of a known class II-T-cell receptor site. The synthetic peptide, now containing both sites, is injected without coupling and used to induce an antibody response. The first experiments using this approach look very promising, and this may become an important alternative to coupling with carrier proteins.

Peptides usually are synthesized with an automated machine using solid-phase techniques. The methods for synthesis and purification of the peptide are beyond the scope of this book. However, to judge the success of the coupling reaction and to determine the number of moles of peptide bound to the carrier, a small proportion of the peptide needs to be labeled. This can be done by including a small amount of  $^{14}\text{C}$ -labeled amino acid in the synthesis or by iodinating a sample of the peptides on a tyrosine or histidine residue (see p. 324) after the synthesis. A small sample of these iodinated peptides can then be added to the coupling reactions to ascertain the success of the coupling.

During immunization, antibodies to the carrier proteins or the coupling agent will also be produced, and these are normally removed by affinity-purifying the anti-peptide antibodies on a column prepared with conjugates of the peptide and a second carrier molecule. Techniques for affinity purification of the antibodies are described in general on p. 313.

### Designing the Peptide

Probably the most frequently asked question concerning synthetic peptides is what sequence should be used for the immunogen (reviewed in Doolittle 1986). Although there is no one correct answer, enough anti-peptide antibodies have been raised to make suggestions for peptide choices. However, preparing anti-peptide antibodies is still an empirical exercise. What works well for one immunogen may fail completely for another.

### Choosing the Appropriate Peptide Sequence

With careful synthesis, coupling, and immunizations, most sequences can be used to induce antibodies specific for the peptide itself. When considering which sequence to use, most people actually want to know how likely will it be that the anti-peptide antibodies will recognize the native protein. Early work suggested that peptides containing hydrophilic amino acids (Hopp and Woods 1981, 1983; Kyte and Doolittle 1982) and proline residues were more likely to be exposed on the surface of the native protein than other sequences, and many peptides have been prepared using these criteria. In assessing the value of these criteria, hydrophilicity is required but is not sufficient to predict the surface location of a particular sequence. Many strongly hydrophilic amino acid sequences are buried in water pockets or form inter- or intramolecular bonds and are thus excluded from interactions with anti-native antibodies. Therefore, hydrophilicity can be thought of as required but not sufficient for choosing peptide sequences (see p. 661 for hydrophilicity values). Hydrophilic peptides are also more likely to be soluble for coupling reactions.

The presence of proline residues in synthetic peptides originally was suggested because  $\beta$ -turns often form portions of known epitopes. However, the presence of proline residues in peptides does not have much predictive value when antisera are tested for binding to the surface of native proteins. Although many excellent anti-peptide antisera have been prepared against sequences with proline residues, there is not sufficient evidence to target prolines when designing peptides.

More recently, several workers have noted that carboxy-terminal sequences often are exposed and can be targeted for anti-peptide sequences. Although using carboxy-terminal sequences does not guarantee that the resulting antibodies will recognize the native protein, a surprisingly high percentage will. Similarly, many amino-terminal regions are exposed, and these also may make good targets.

Another potentially useful parameter for selecting peptide sequences is the "mobility" of the amino acid residues. Originally, it was noted that the regions of a protein that become epitopes often have a higher temperature than other regions, as determined by NMR and X-ray structure (Moore and Williams 1980; Robinson et al. 1983; Tainer et al. 1984; Westhof et al. 1984). Higher temperature in crystallography and NMR distinguishes regions that are more mobile from

regions that are more static. These observations have led to the suggestion that stretches of amino acids that are more flexible are more likely to be epitopes. In the preparation of anti-peptide antibodies, when a peptide is coupled to a carrier molecule, it has a different local environment than in the original protein. When choosing a sequence for antibody production, a region of the protein that is more flexible will be more likely over time to form a structure that is similar to the peptide-carrier conjugate. Although the measure of mobility may become a useful criterion for selecting good peptide sequences, it has not been tested in enough detail to determine whether it will have any predictive value.

At present, a reasonable order of suggestions for choosing peptide sequences would be:

1. If possible, use more than one peptide.
2. Use the carboxyl-terminal sequence if it is hydrophilic and if a suitable coupling group is available or can be added.
3. Use the amino-terminal sequence if it is hydrophilic and if a suitable coupling group is available or can be added.
4. Use internal hydrophilic regions; perhaps using longer peptides.

#### Size of the Peptide

The smallest synthetic peptides that will consistently elicit antibodies that bind to the original protein are 6 residues in length. Responses to smaller peptides are typically weak or will not recognize the protein of interest, either in a native or denatured state. Since epitopes consisting of smaller regions have been reported, the lower limit presumably reflects the difficulty of recognizing the smaller peptides coupled to carriers. With peptides of 6 amino acids or slightly larger, the responses vary. Some will generate good antibodies and some will not. Generally, peptides of approximately 10 residues should be used as a lower limit for coupling.

In the literature two strategies are suggested for peptide length. One school suggests using long peptides (up to 40 amino acids long) to increase the number of possible epitopes, while other authors argue that smaller peptides are adequate and their use ensures that the site-specific character of anti-peptide antibodies is retained. Both strategies have been used successfully. Two important preliminary questions to consider are: (1) Does the anti-peptide serum need to recognize the native protein? If so, use longer peptides or prepare anti-peptide antisera against multiple peptides. (2) How good is your peptide synthesis facility? Peptides over 20 residues in length are increasingly difficult to synthesize, yielding products with inappropriate side reactions. Longer peptides also are more likely to contain residues that make the coupling to carrier molecules more difficult. The correct decision between peptides with 10–15 residues and longer peptides will depend on the experimental design and will normally be a compromise between these factors. The safest choice, but also the most expensive, will be to prepare multiple small peptides of 10–15 amino acids in length from various regions of the sequence.

#### Coupling Strategy

When choosing the sequence for a synthetic peptide, one factor that often is overlooked is the method of coupling. Most coupling methods rely on the presence of free amino, sulfhydryl, phenolic, or carboxylic acid groups. Free amino groups used for coupling will be found on lysine side chains or on the amino-terminal residue. Sulfhydryl groups are found on cysteine side chains, phenolic groups on tyrosines, and carboxylic acid groups on aspartic acids, glutamic acids, and the carboxy-terminal residue. Coupling methods should be used that link the peptide to the carrier via either the carboxy- or amino-terminal residue. When preparing antibodies against the carboxy-terminal region of the protein, the coupling should be done through the amino terminal fragments should be done through the carboxy-terminal region of the peptide. For internal fragments, the major consideration is that the peptide be coupled by an end and not through a central residue.

The easiest strategy to manipulate the type of coupling is to add an extra amino acid on either the amino or carboxyl terminus to allow potentially can bind to an internal residue should be avoided. Similarly, coupling methods should be chosen that will bind to only one amino acid, if possible. If multiple coupling sites are possible, they should be localized to either the amino or carboxyl terminus, and the coupling should be adjusted to link only through one site per peptide on average. It is important to remember that it is often easier to use different peptides than design elaborate coupling schemes.

#### Choosing the Appropriate Carrier

Many different carrier proteins can be used for coupling with synthetic peptides. The two most commonly used are keyhole limpet hemacyanin (KLH) and bovine serum albumin (BSA). Both work well in most cases, but each has disadvantages. Because of its large size, KLH is more likely to precipitate during cross-linking, and this can make handling KLH difficult in some cases. On the other hand, BSA is very soluble, but often is a good immunogen in its own right. For most purposes, either carrier will be adequate. Use whichever is more convenient.

Three other carriers that are used occasionally are ovalbumin, mouse serum albumin, or rabbit serum albumin. Ovalbumin can be used as a good carrier for most purposes. It is also a good choice for a second carrier when checking that antibodies are specific for the peptide itself and not the carrier. MSA or RSA may be used when the antibody response to the carrier molecule must be kept to a minimum.

BSA has 59 lysine (30–35 are available for coupling), 19 tyrosine, 35 cysteine, 39 aspartic acid, and 59 glutamic acid residues. Ovalbumin has 20 lysine, 10 tyrosine, 6 cysteine, 14 aspartic acid, and 33 glutamic acid residues.

# ***Molecular Cloning***

**A LABORATORY MANUAL**

**SECOND EDITION**

**Nina Irwin**

*Associate Author*

**Nancy Ford**

*Managing Editor*

**Chris Nolan**

*Editor*

**Michele Ferguson**

*Associate Editor*

**Michael Orkter**

*Illustrator*

**J. Sambrook**

UNIVERSITY OF TEXAS SOUTH-WESTERN MEDICAL CENTER

**E.F. Fritsch**

GENETICS INSTITUTE

**T. Maniatis**

HARVARD UNIVERSITY



*Cold Spring Harbor Laboratory Press  
1989*

# Molecular Cloning

A LABORATORY MANUAL  
SECOND EDITION

All rights reserved  
© 1989 by Cold Spring Harbor Laboratory Press  
Printed in the United States of America

9 8 7 6 5 4 3 2 1

Book and cover design by Emily Horvitz

Cover: The electron micrograph of bacteriophage  $\lambda$  particles stained with uranyl acetate was digitized and assigned false color by computer. (Thomas R. Broker, Louise T. Chow, and James I. Garrels)

Cataloging in Publications data

Sambrook, Joseph  
Molecular cloning : a laboratory manual / E.F. Fritsch, T. Maniatis—2nd ed.  
p. cm.

Bibliography: p.  
Includes index.

ISBN 0-87969-309-6

1. Molecular cloning—Laboratory manuals. 2. Eukaryotic cells—Laboratory manuals. I. Fritsch, Edward F. II. Maniatis, Thomas

III. Title.

QH442.2.M26 1987  
574.873224—dc19

87-35464

Researchers using the procedures of this manual do so at their own risk. Cold Spring Harbor Laboratory makes no representations or warranties with respect to the material set forth in this manual and has no liability in connection with the use of these materials.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cold Spring Harbor Laboratory Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$0.10 per page is paid directly to CCC, 21 Congress St., Salem MA 01970. (0-87969-309-6/89 \$0.00 + \$0.10) This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

All Cold Spring Harbor Laboratory Press publications may be ordered directly from Cold Spring Harbor Laboratory, Box 100, Cold Spring Harbor, New York 11724. Phone: 1-800-943-4388. In New York (516)367-8423.

## Contents

### BOOK 1

#### 1

### Plasmid Vectors

#### Essential Features of Plasmids 1.3

Replication and Incompatibility 1.3

Mobilization 1.5

Selectable Markers 1.5

#### Plasmid Vectors 1.7

#### DEVELOPMENT OF PLASMID CLONING VECTORS 1.7

Plasmid Vectors That Permit Biochemical Identification of Recombinant

Clones 1.8

Plasmid Vectors Carrying Origins of Replication Derived from Single-stranded

Bacteriophages 1.9

Plasmid Vectors Carrying Bacteriophage Promoters 1.9

Plasmid Vectors That Allow Direct Selection of Recombinant Clones 1.9

Plasmid Expression Vectors 1.10

#### COMMONLY USED PLASMID VECTORS 1.11

pBR322 1.12

pUC18, pUC19 1.13

pUC118, pUC119 1.14

pSP64, pSP65, pGEM-3, pGEM-3Z, pGEM-3Z(-), pGEM-4, pGEM-4Z 1.15

pAN13 1.19

BLUESCRIPT M13+, M13- 1.20

#### Extraction and Purification of Plasmid DNA 1.21

Growth of the Bacterial Culture 1.21

Harvesting and Lysis of the Bacteria 1.22

Purification of Plasmid DNA 1.23

#### SMALL-SCALE PREPARATIONS OF PLASMID DNA 1.25

Harvesting and Lysis of Bacteria 1.25

Identification of Bacterial Colonies That Contain Recombinant Plasmids	1.85
RESTRICTION ANALYSIS OF SMALL-SCALE PREPARATIONS OF PLASMID DNA	1.85
α-COMPLEMENTATION	1.85
Testing Bacteria for α-Complementation	1.86
INSERTIONAL INACTIVATION	1.87
SCREENING BY HYBRIDIZATION	1.90
Transferring Small Numbers of Colonies to Nitrocellulose Filters	1.92
Replicating Colonies onto Nitrocellulose Filters	1.93
METHOD 1	1.93
METHOD 2	1.96
Lysis of Colonies and Binding of DNA to Nitrocellulose Filters	1.98
METHOD 1	1.98
METHOD 2	1.100
Hybridization to Nitrocellulose Filters Containing Replicas of Bacterial Colonies	1.101
References	1.105

## 2

### Bacteriophage λ Vectors

Molecular Biology of Bacteriophage λ	2.3
THE LYTIC CYCLE	2.3
Adsorption	2.3
Immediate Early Transcription	2.5
Delayed Early Transcription	2.5
DNA Replication	2.5
Late Transcription	2.5
Assembly	2.7
Lysis	2.8
LYSOGENY	2.8
Bacteriophage λ Vectors	2.9
CONSTRUCTION OF BACTERIOPHAGE λ VECTORS: A BRIEF HISTORY	2.9
CHOOSING THE APPROPRIATE BACTERIOPHAGE λ VECTOR	2.11
MAPS OF BACTERIOPHAGE λ VECTORS	2.15
λ	2.17
CHARON 4A	2.18
CHARON 91A	2.20
CHARON 32	2.22
CHARON 33	2.24

HARVESTING	1.25
LYSIS BY ALKALI	1.25
LYSIS BY BOILING	1.29
Solving Problems That Arise with Mini-preparations of Plasmid DNA	1.31
Rapid Disruption of Bacterial Colonies to Test the Size of Plasmids	1.32
LARGE-SCALE PREPARATIONS OF PLASMID DNA	1.33
Amplification of Plasmids in Rich Medium	1.33
Harvesting and Lysis of Bacteria	1.34
HARVESTING	1.34
LYSIS BY BOILING	1.34
LYSIS BY SODIUM DODECYL SULFATE	1.36
LYSIS BY ALKALI	1.38
PURIFICATION OF PLASMID DNA	1.40
Purification of Plasmid DNA by Precipitation with Polyethylene Glycol	1.40
Purification of Closed Circular DNA by Equilibrium Centrifugation in CsCl-Ethidium Bromide Gradients	1.42
CONTINUOUS GRADIENTS	1.42
DISCONTINUOUS GRADIENTS	1.44
Removal of Ethidium Bromide from DNAs Purified by Equilibrium Centrifugation in CsCl-Ethidium Bromide Gradients	1.46
METHOD 1: EXTRACTION WITH ORGANIC SOLVENTS	1.46
METHOD 2: ION-EXCHANGE CHROMATOGRAPHY	1.47
Decontamination of Ethidium Bromide Solutions	1.49
DECONTAMINATION OF CONCENTRATED SOLUTIONS OF ETHIDIUM BROMIDE	1.49
DECONTAMINATION OF DILUTE SOLUTIONS OF ETHIDIUM BROMIDE	1.50
Removal of RNA from Preparations of Plasmid DNA	1.51
CENTRIFUGATION THROUGH 1 M NaCl	1.51
CHROMATOGRAPHY THROUGH BIO-GEL A-150m OR SEPHAROSE CL-4B	1.52

### Strategies for Cloning in Plasmid Vectors 1.53

STRATEGIES FOR LIGATION	1.53
The Nature of the Ends of the Foreign DNA Fragment	1.53
FRAGMENTS CARRYING NONCOMPLEMENTARY PROTRUDING TERMINI	1.53
FRAGMENTS CARRYING IDENTICAL TERMINI (BLUNT-ENDED OR PROTRUDING)	1.56
FRAGMENTS CARRYING BLUNT ENDS	1.56
The Nature of the Restriction Sites in the Plasmid Vector and the Foreign DNA	1.59

### DEPHOSPHORYLATION OF LINEARIZED PLASMID DNA 1.60

Test Ligations and Transformations	1.60
------------------------------------	------

### LIGATION REACTIONS 1.63

Setting Up Ligation Reactions Between Foreign DNA and Plasmid Vectors	1.63
Ligation of Cohesive Termini	1.68
Ligation of Blunt-ended DNA	1.70
CONDENSING AGENTS	1.70
Rapid Cloning in Plasmid Vectors	1.72

### Preparation and Transformation of Competent E. coli 1.74

Transformation of E. coli by High-voltage Electroporation (Electrotransformation)	1.75
Protocol I: Preparation of Fresh or Frozen Competent E. coli	1.76
Protocol II: Fresh Competent E. coli Prepared Using Calcium Chloride	1.82

CHARON 34 2.26  
 CHARON 35 2.28  
 CHARON 40 2.30  
 EMBL3A 2.32  
 A2001 2.34  
 ADASH 2.36  
 AFTX 2.38  
 Agt10 2.40  
 Agt11 2.42  
 Agt18 2.44  
 Agt20 2.46  
 Agt22 2.48  
 AORF8 2.50  
 AZAPR 2.52

CHOOSING A BACTERIAL HOST FOR BACTERIOPHAGE  $\lambda$  VECTORS 2.55  
 Restriction and Modification 2.55  
 Amber Suppressors 2.55  
 Recombination Systems 2.55

Bacteriophage  $\lambda$  Growth, Purification, and DNA Extraction 2.60

PLAQUE PURIFICATION OF BACTERIOPHAGE  $\lambda$  2.60

Preparation of Plating Bacteria 2.60

Plating Bacteriophage  $\lambda$  2.61

Picking Bacteriophage  $\lambda$  Plaques 2.63

PREPARING STOCKS OF BACTERIOPHAGE  $\lambda$  FROM SINGLE PLAQUES 2.64

Plate Lysate Stocks 2.64

PREPARATION OF PLATE LYSATE STOCKS: PROTOCOL I 2.65

PREPARATION OF PLATE LYSATE STOCKS: PROTOCOL II 2.66

Small-scale Liquid Cultures 2.67

Long-term Storage of Bacteriophage  $\lambda$  Stocks 2.68

LARGE-SCALE PREPARATION OF BACTERIOPHAGE  $\lambda$  2.69

Infection at Low Multiplicity 2.70

Infection at High Multiplicity 2.72

PURIFICATION OF BACTERIOPHAGE  $\lambda$  2.73

Standard Method for Purification of Bacteriophage  $\lambda$  2.73

Alternative Methods for Purification of Bacteriophage  $\lambda$  2.77

PELLETING BACTERIOPHAGE PARTICLES 2.77

GLYCEROL STEP GRADIENT 2.78

EQUILIBRIUM CENTRIFUGATION IN CESIUM CHLORIDE 2.79

EXTRACTION OF BACTERIOPHAGE  $\lambda$  DNA 2.80

Cloning in Bacteriophage  $\lambda$  2.82

PREPARATION OF VECTOR DNA 2.82

Digestion of Bacteriophage  $\lambda$  DNA with Restriction Enzymes 2.83

Purification of Bacteriophage  $\lambda$  Arms 2.85

CENTRIFUGATION THROUGH SUCROSE DENSITY GRADIENTS 2.85

CENTRIFUGATION THROUGH SODIUM CHLORIDE GRADIENTS 2.88

Preparation of Vectors Treated with Alkaline Phosphatase 2.90

Digestion of Bacteriophage  $\lambda$  Vectors with Two Restriction Enzymes 2.92

Ligation of Bacteriophage  $\lambda$  Arms to Fragments of Foreign DNA 2.94

PACKAGING OF BACTERIOPHAGE  $\lambda$  DNA IN VITRO 2.95  
 Maintenance and Testing of Lysoforms of Bacteriophage  $\lambda$  2.96  
 Preparation of Packaging Extracts and Packaging of Bacteriophage  $\lambda$  DNA In Vitro 2.98

PROTOCOL I: PREPARATION OF PACKAGING EXTRACTS FROM TWO LYSOGENS 2.100  
 PROTOCOL I: PACKAGING IN VITRO USING TWO EXTRACTS 2.104  
 PROTOCOL II: PREPARATION OF PACKAGING EXTRACTS FROM ONE LYSOGEN 2.105  
 PROTOCOL II: PACKAGING IN VITRO USING ONE EXTRACT 2.107

Identification and Analysis of Recombinants 2.108

IN SITU HYBRIDIZATION OF BACTERIOPHAGE  $\lambda$  PLAQUES 2.108

Immobilization of Bacteriophage  $\lambda$  Plaques on Nitrocellulose Filters or Nylon Membranes 2.109

Immobilization of Bacteriophage  $\lambda$  Plaques on Nitrocellulose Filters Following In Situ Amplification 2.112

Hybridization to Nitrocellulose Filters Containing Replicas of Bacteriophage  $\lambda$  Plaques 2.114

RAPID ANALYSIS OF BACTERIOPHAGE  $\lambda$  ISOLATES 2.118

Plate Lysate Method 2.118

Liquid Culture Method 2.121

References 2.122

## 3

## Cosmid Vectors

Cloning in Cosmid Vectors 3.5

Cosmid Vectors 3.7

COSMID VECTORS FOR PROPAGATION OF EUKARYOTIC DNA IN BACTERIA 3.9

pJB8 3.9

cERB 3.13

pos1EMBL 3.17

COSMID VECTORS FOR TRANSFECTION OF MAMMALIAN CELLS 3.18

pHCT8-2cat/4 3.19

pCV103, pCV107, pCV108 3.19

PTM, PMCS, pNNL 3.19

pSG274 3.19

pSG202, cos203 3.19

pWE15, pWE16 3.21

CHARONID 9 VECTORS 3.25

Construction of Genomic DNA Libraries in Cosmid Vectors 3.27

CLONING IN PHOSPHATASE-TREATED COSMID VECTORS 3.28



Preparation of Vector DNA	3.28	Plating Bacteriophage M13	4.22
TEST LIGATION	3.29	Picking Bacteriophage M13 Plaques	4.24
Partial Digestion of Eukaryotic DNA with MboI or Sau3AI	3.32	PREPARING STOCKS OF BACTERIOPHAGE M13 FROM SINGLE PLAQUES	4.25
Ligation and Packaging	3.33	Liquid Cultures	4.25
CLONING IN COSMID VECTORS DIGESTED WITH TWO RESTRICTION ENZYMES AND TREATED WITH PHOSPHATASE	3.35	PREPARATION OF BACTERIOPHAGE M13 DNA	4.26
Preparation of Vector DNA	3.36	Small-scale Preparations of the Replicative Form of Bacteriophage M13 DNA	4.26
Treatment of Eukaryotic DNA with Alkaline Phosphatase	3.38	Large-scale Preparations of Single-stranded Bacteriophage M13 DNA	4.29
Ligation and Packaging	3.40	Large-scale Preparations of the Replicative Form of Bacteriophage M13 DNA	4.31
PREPARATION OF VECTORS CONTAINING TWO cos SITES	3.42	Large-scale Preparations of Single-stranded Bacteriophage M13 DNA	4.32
Amplification and Storage of Cosmid Libraries	3.44	Cloning into Bacteriophage M13 Vectors and Transfection of Competent Bacteria	4.33
Replica Filters	3.46	Cloning DNA Fragments into Bacteriophage M13 Vectors	4.35
Amplification of Cosmid Libraries in Liquid Culture	3.50	Preparation of Competent Bacteria	4.36
Preparation of a Transducing Lysate of Packaged Cosmids	3.52	Transfection of Competent Bacteria with Bacteriophage M13 DNA	4.37
Problems Commonly Encountered When Using Cosmids	3.54	Identification and Analysis of Recombinants	4.39
References	3.56	Direct Gel Electrophoresis	4.41
		In Situ Hybridization of Bacteriophage M13 Plaques	4.41
		Analysis of Small-scale Preparations of the Replicative Form of Bacteriophage M13 DNA	4.41
		Testing the Orientation of DNA Cloned in Bacteriophage M13 Vectors	4.42
		Cloning in Phagemids	4.44
		Growth of M13KO7	4.47
		Production of Single-stranded Phagemid DNA	4.48
		Screening Colonies by Superinfection	4.49
		References	4.51
		Restriction and DNA Methylation Enzymes	5.3
		LIGATION OF TERMINI CREATED BY RESTRICTION ENZYMES	5.10
		Compatible Cohesive Termini	5.10
		Blunt Ends	5.11
		Incompatible Cohesive Termini	5.11
		ISOSCHIZOMERS	5.14

## Gel Electrophoresis of DNA

### Agarose Gel Electrophoresis 6.3

Factors Affecting the Rate of DNA Migration in Agarose Gels 6.4

MOLECULAR SIZE OF THE DNA 6.4

AGAROSE CONCENTRATION 6.4

CONFORMATION OF THE DNA 6.5

APPLIED VOLTAGE 6.6

DIRECTION OF THE ELECTRIC FIELD 6.6

BASE COMPOSITION AND TEMPERATURE 6.6

PRESENCE OF INTERCALATING DYES 6.6

COMPOSITION OF THE ELECTROPHORESIS BUFFER 6.6

Apparatuses Used for Agarose Gel Electrophoresis 6.8

### PREPARATION AND EXAMINATION OF AGAROSE GELS 6.9

Preparation of an Agarose Gel 6.9

Minigels 6.14

Staining DNA in Agarose Gels 6.15

Decontamination of Ethidium Bromide Solutions 6.16

DECONTAMINATION OF CONCENTRATED SOLUTIONS OF ETHIDIUM BROMIDE 6.16

DECONTAMINATION OF DILUTE SOLUTIONS OF ETHIDIUM BROMIDE 6.17

Photography 6.19

Alkaline Agarose Gels 6.20

### RECOVERY AND PURIFICATION OF DNA FRACTIONATED ON AGAROSE GELS 6.22

Electrophoresis onto DEAE-cellulose Membrane 6.24

Electroelution into Dialysis Bags 6.28

Recovery of DNA from Low-melting-temperature Agarose Gels 6.30

Purification of DNA Recovered from Agarose Gels 6.32

PASSAGE THROUGH DEAE-SEPHACEL 6.32

EXTRACTION WITH ORGANIC SOLVENTS 6.34

### Polyacrylamide Gel Electrophoresis 6.36

#### PREPARATION OF NONDENATURING POLYACRYLAMIDE GELS 6.39

#### DETECTION OF DNA IN POLYACRYLAMIDE GELS 6.44

Staining with Ethidium Bromide 6.44

Autoradiography 6.45

UNFIXED, WET GELS 6.46

FIXED, DRIED GELS 6.46

#### ISOLATION OF DNA FRAGMENTS FROM POLYACRYLAMIDE GELS 6.46

"Crush and Soak" Method 6.46

### Other Types of Gels 6.49

#### STRAND SEPARATING GELS 6.49

#### DENATURING GRADIENT POLYACRYLAMIDE GELS 6.49

### DNA METHYLATION 5.15

Methylation by Commonly Used Strains of *E. coli* 5.15

*dam* METHYLASE 5.15

*dcm* METHYLASE 5.15

METHYLATION-DEPENDENT RESTRICTION SYSTEMS IN *E. coli*

*M.EcoRI* METHYLASE 5.15

Modification of Restriction Sites by DNA Methylation 5.16

Influence of Methylation on DNA Mapping 5.26

### DIGESTING DNA WITH RESTRICTION ENZYMES 5.28

Setting Up Digestions with Restriction Enzymes 5.31

### Other Enzymes Used in Molecular Cloning 5.33

#### DNA POLYMERASES 5.35

DNA Polymerase I (Holoenzyme) 5.36

Large Fragment of DNA Polymerase I (Klenow Fragment) 5.40

Bacteriophage T4 DNA Polymerase 5.44

Bacteriophage T7 DNA Polymerase 5.48

Modified Bacteriophage T7 DNA Polymerase (Sequenase™) 5.49

Taq DNA Polymerase 5.50

Reverse Transcriptase (RNA-dependent DNA Polymerase) 5.52

Terminal Transferase (Terminal Deoxynucleotidyl Transferase) 5.56

#### DNA-DEPENDENT RNA POLYMERASES 5.58

Bacteriophage SP6 and Bacteriophages T7 and T3 RNA

Polymerases 5.58

#### LIGASES, KINASES, AND PHOSPHATASES 5.61

Bacteriophage T4 DNA Ligase 5.62

*E. coli* DNA Ligase 5.64

Bacteriophage T4 RNA Ligase 5.66

Bacteriophage T4 Polynucleotide Kinase 5.68

Alkaline Phosphatases 5.72

#### NUCLEASES 5.73

Nuclease BAL 31 5.73

Nuclease S1 5.78

Mung-bean Nuclease 5.80

Ribonuclease A 5.81

Ribonuclease T1 5.82

Deoxyribonuclease I 5.83

Exonuclease III 5.84

Bacteriophage  $\lambda$  Exonuclease 5.86

### DNA-binding Proteins 5.87

Single-stranded DNA-binding Protein (SSB) 5.87

RecA Protein 5.88

Topoisomerase I 5.89

### References 5.90

## **PULSED-FIELD GEL ELECTROPHORESIS 6.50**

- Design of the Apparatus 6.51
- Staining DNA Separated by Pulsed-field Gel Electrophoresis 6.52
- Preparation of DNA for Pulsed-field Gel Electrophoresis 6.53
- ISOLATION OF INTACT DNA FROM MAMMALIAN CELLS 6.53
- ISOLATION OF INTACT DNA FROM YEAST 6.53
- RESTRICTION ENZYME DIGESTION OF DNA IN AGAROSE BLOCKS 6.57
- Markers for Pulsed-field Gel Electrophoresis 6.58

## **References 6.60**

## **7**

## **Extraction, Purification, and Analysis of Messenger RNA from Eukaryotic Cells**

### **Extraction and Purification of RNA 7.3**

#### **CONTROLLING RIBONUCLEASE ACTIVITY 7.3**

- Laboratory Procedures 7.3
- Inhibitors of Ribonucleases 7.4
- Methods That Disrupt Cells and Inactivate Ribonucleases Simultaneously 7.5

#### **ISOLATION OF RNAs 7.6**

- Isolation of Total RNA from Mammalian Cells 7.6
- Rapid Isolation of Total RNA from Mammalian Cells 7.10
- Isolation of Cytoplasmic RNA from Mammalian Cells 7.12
- Isolation of Total RNA from Eggs and Embryos 7.16
- Isolation of Total RNA by Extraction with Strong Denaturants 7.18
- EXTRACTION OF RNA WITH GUANIDINIUM THIOCYANATE FOLLOWED BY CENTRIFUGATION IN CESIUM CHLORIDE SOLUTIONS 7.19
- EXTRACTION OF RNA WITH GUANIDINE HCl AND ORGANIC SOLVENTS 7.23

#### **SELECTION OF POLY(A)<sup>+</sup> RNA 7.26**

#### **FRACTIONATION OF RNA BY SIZE IN THE PRESENCE OF METHYLMERCURIC HYDROXIDE 7.30**

- Electrophoresis of RNA through Agarose Gels Containing Methylmercuric Hydroxide 7.31
- RECOVERY OF RNA FROM AGAROSE GELS CONTAINING METHYLMERCURIC HYDROXIDE 7.33
- Fractionation of RNA by Centrifugation through Sucrose Gradients Containing Methylmercuric Hydroxide 7.35

#### **Analysis of RNA 7.37**

#### **NORTHERN HYBRIDIZATION 7.39**

- Electrophoresis of RNA after Denaturation with Glyoxal and Dimethyl Sulfoxide 7.40
- Electrophoresis of RNA through Gels Containing Formaldehyde 7.43
- Transfer of Denatured RNA to Nitrocellulose Filters 7.46

- Transfer of Denatured RNA to Nylon Membranes 7.49
- Staining RNA Before and After Transfer to Nitrocellulose Filters 7.51
- METHOD 1 7.51
- METHOD 2 7.51
- Hybridization and Autoradiography 7.52
- DOT AND SLOT HYBRIDIZATION OF RNA 7.53
- Slot Hybridization of RNA 7.54
- Slot Hybridization of Cytoplasmic RNA 7.56
- MAPPING RNA WITH NUCLEASE S1 7.58
- Mapping of RNA with Nuclease S1 and Double-stranded DNA Probes 7.62
- Mapping of RNA with Nuclease S1 and Single-stranded DNA Probes 7.66
- MAPPING OF RNA WITH RIBONUCLEASE AND RADIOLABELLED RNA PROBES 7.71
- ANALYSIS OF RNA BY PRIMER EXTENSION 7.79
- References 7.84

## Construction and Analysis of cDNA Libraries

- Strategies for cDNA Cloning* 8.3
- PREPARATION OF mRNA FOR cDNA CLONING* 8.3
- Source of the mRNA 8.3
- Integrity of the mRNA 8.4
- Abundant mRNAs 8.6
- Low-abundance mRNAs 8.6
- Methods of Enrichment 8.6
- FRACTIONATION OF mRNA BY SIZE 8.8
- FRACTIONATION OF cDNA 8.8
- IMMUNOLOGICAL PURIFICATION OF POLYSOMES 8.9
- SYNTHESIS OF THE FIRST STRAND OF cDNA* 8.11
- SYNTHESIS OF THE SECOND STRAND OF cDNA* 8.14
- Self-priming 8.14
- Replacement Synthesis of the Second Strand of cDNA 8.15
- Primer Synthesis of the Second Strand of cDNA 8.17
- MOLECULAR CLONING OF DOUBLE-STRANDED cDNA* 8.21
- Homopolymeric Tailing 8.21
- Synthetic DNA Linkers and Adapters 8.23
- Alternative Methods of Cloning cDNA 8.27
- mRNA-cDNA CLONING 8.27
- SEQUENTIAL ADDITION OF DIFFERENT LINKERS 8.27
- cDNA CLONING IN OKAYAMA-BERG VECTORS 8.29
- cDNA CLONING WITH PRIMER-ADAPTERS 8.30
- cDNA CLONING IN SINGLE-STRANDED VECTORS 8.32
- BACTERIOPHAGE  $\lambda$  VECTORS USED FOR CLONING OF cDNA* 8.36
- Bacteriophage  $\lambda$  Vectors  $\lambda$ gt10 and  $\lambda$ gt11 8.36
- $\lambda$ gt10 8.36
- $\lambda$ gt11 8.37
- Other Bacteriophage  $\lambda$  Vectors Used for cDNA Cloning 8.38
- $\lambda$ ORF8 8.39
- $\lambda$ gt18,  $\lambda$ gt19 8.41
- $\lambda$ gt20,  $\lambda$ gt21 8.42
- $\lambda$ gt22,  $\lambda$ gt23 8.42
- $\lambda$ ZAP 8.44
- IDENTIFICATION OF cDNA CLONES OF INTEREST* 8.46
- Methods of Screening 8.46
- NUCLEIC ACID HYBRIDIZATION 8.46
- IMMUNOLOGICAL DETECTION OF SPECIFIC ANTIGENS 8.49
- SIB SELECTION OF cDNA CLONES 8.50
- Methods to Validate Clones of cDNA 8.51
- Protocols for cDNA Cloning* 8.53

- CONSTRUCTING cDNA LIBRARIES IN BACTERIOPHAGE  $\lambda$  VECTORS* 8.54
- Precautions 8.54
- Protocol for the Synthesis of the First Strand of cDNA 8.60
- Protocol for the Synthesis of the Second Strand of cDNA 8.64
- Methylation of cDNA 8.66
- Ligation to Synthetic Phosphorylated Linkers 8.68
- Size Selection of cDNA 8.70
- Ligation to Bacteriophage  $\lambda$  Arms 8.73
- Analysis of cDNA Inserts 8.76
- Generation of a Complete cDNA Library 8.77
- Amplification of cDNA Libraries 8.78
- AMPLIFICATION OF LIBRARIES CONSTRUCTED IN BACTERIOPHAGE  $\lambda$ gt10: SELECTION AGAINST PARENTAL BACTERIOPHAGES 8.78
- AMPLIFICATION OF LIBRARIES CONSTRUCTED IN BACTERIOPHAGE  $\lambda$ gt11 AND ITS DERIVATIVES AND  $\lambda$ ZAP OR  $\lambda$ ZAP II 8.79
- PROBLEMS COMMONLY ENCOUNTERED WITH cDNA CLONING* 8.80
- References 8.82

## 9

## Analysis and Cloning of Eukaryotic Genomic DNA

- Vectors Used to Construct Eukaryotic Genomic DNA Libraries* 9.4
- Bacteriophage  $\lambda$  and Cosmid Vectors 9.4
- Yeast Artificial Chromosome System 9.5
- BACTERIOPHAGE  $\lambda$  VECTORS RECOMMENDED FOR CONSTRUCTION OF LIBRARIES OF EUKARYOTIC GENOMIC DNA* 9.7
- COSMID VECTORS RECOMMENDED FOR CONSTRUCTION OF LIBRARIES OF EUKARYOTIC GENOMIC DNA* 9.13
- Isolation of High-molecular-weight DNA from Mammalian Cells* 9.14
- Isolation of DNA from Mammalian Cells: Protocol I 9.16
- Isolation of DNA from Mammalian Cells: Protocol II 9.20
- Isolation of DNA from Mammalian Cells: Protocol III 9.22
- Partial Digestion of High-molecular-weight Eukaryotic DNA with Restriction Enzymes* 9.24
- Pilot Experiments 9.24
- Large-scale Preparation of Partially Digested DNA 9.27
- Partial Filling of Recessed 3' Termini of Fragments of Genomic DNA 9.29
- Amplification of a Genomic DNA Library 9.30

**Analysis of Genomic DNA by Southern Hybridization 9.31**  
**SEPARATION OF RESTRICTION FRAGMENTS OF MAMMALIAN GENOMIC DNA BY AGAROSE GEL ELECTROPHORESIS 9.32**

**TRANSFER OF DNA FROM AGAROSE GELS TO SOLID SUPPORTS 9.34**

- Transfer of DNA to Nitrocellulose Filters 9.38
- CAPILLARY TRANSFER OF DNA TO NITROCELLULOSE FILTERS 9.38
- SIMULTANEOUS TRANSFER OF DNA FROM A SINGLE AGAROSE GEL TO TWO NITROCELLULOSE FILTERS 9.41
- Transfer of DNA from Agarose Gels to Nylon Membranes 9.42
- CAPILLARY TRANSFER OF DNA TO NYLON MEMBRANES UNDER NEUTRAL CONDITIONS 9.44
- CAPILLARY TRANSFER OF DNA TO NYLON MEMBRANES UNDER ALKALINE CONDITIONS 9.46

**HYBRIDIZATION OF RADIO-LABELED PROBES TO IMMOBILIZED NUCLEIC ACIDS 9.47**

- Hybridization of Radiolabeled Probes to Nucleic Acids Immobilized on Nitrocellulose Filters or Nylon Membranes 9.52
- Hybridization of Radiolabeled Oligonucleotides to Genomic DNA 9.56
- Removal of Radiolabeled Probes from Nitrocellulose Filters and Nylon Membranes 9.58
- REMOVING PROBES FROM NITROCELLULOSE FILTERS 9.58
- REMOVING PROBES FROM NYLON MEMBRANES 9.58

**References 9.59**

**10**

**Preparation of Radiolabeled DNA and RNA Probes**

**Synthesis of Uniformly Labeled Double-stranded DNA Probes 10.6**

- NICK TRANSLATION OF DNA 10.6
- Stock Solutions Used in Nick Translation 10.7
- Protocol for Nick Translation 10.8
- Alternative Protocol for Nick Translation 10.11

**SYNTHESIS OF UNIFORMLY LABELED DNA PROBES USING RANDOM OLIGONUCLEOTIDE PRIMERS 10.13**

- Synthesis of Probes from Denatured Double-stranded DNA 10.14
- SYNTHESIS OF RADIO-LABELED PROBES BY PRIMER EXTENSION 10.14
- RADIO-LABELING OF DNA IN THE PRESENCE OF MELTED AGAROSE 10.16

**Preparation of Single-stranded Probes 10.18**

**PRODUCTION OF SINGLE-STRANDED DNA PROBES USING BACTERIOPHAGE M13 VECTORS 10.19**

- Primer: Template Ratios and Nucleotide Concentrations 10.20
- Synthesis of Single-stranded DNA Probes 10.23
- Isolation of Small (< 150 Nucleotides) Probes by Alkaline Chromatography on Sepharose CL-4B 10.25
- Troubleshooting 10.26

**SYNTHESIS OF RNA PROBES BY IN VITRO TRANSCRIPTION OF DOUBLE-STRANDED DNA TEMPLATES BY BACTERIOPHAGE DNA-DEPENDENT RNA POLYMERASES 10.27**  
**Plasmid Vectors for Preparing RNA Probes 10.29**  
**Preparation of DNA Template 10.31**  
**Synthesis of RNA In Vitro 10.32**  
**Synthesis of RNA Probes Radiolabeled to High Specific Activity 10.34**  
**Troubleshooting 10.36**

**SYNTHESIS OF cDNA PROBES 10.38**

- Identification of cDNA Clones 10.38
- DIFFERENTIAL SCREENING 10.38
- ABSORBED PROBES 10.40
- SUBTRACTED LIBRARIES 10.40
- SUBTRACTED PROBES RADIO-LABELED TO HIGH SPECIFIC ACTIVITY 10.43
- Synthesis of Total cDNA Probes Complementary to Single-stranded RNA Using Oligonucleotides as Primers 10.44
- Synthesis of Radiolabeled, Subtracted cDNA Probes Using Oligo(dT) as a Primer 10.46
- Synthesis of Subtracted Probes Radiolabeled to High Specific Activity 10.48

**Labeling the 5' and 3' Termini of DNA 10.51**

**LABELING THE 3' TERMINI OF DOUBLE-STRANDED DNA USING THE KLENOW FRAGMENT OF E. coli DNA POLYMERASE I 10.51**

**LABELING THE 3' TERMINI OF DOUBLE-STRANDED DNA WITH BACTERIOPHAGE T4 DNA POLYMERASE 10.54**

- Rapid End-labeling of DNA 10.54
- Replacement Synthesis 10.56

**LABELING THE 5' TERMINUS OF DNA WITH BACTERIOPHAGE T4 POLYNUCLEOTIDE KINASE 10.59**

- Forward Reaction 10.60
- USING DNA MOLECULES WITH PROTRUDING 5' TERMINI AS SUBSTRATES 10.60
- USING DNA MOLECULES WITH BLUNT ENDS OR RECESSED 5' TERMINI AS SUBSTRATES 10.62
- DEPHOSPHORYLATION OF DNA 10.64
- Exchange Reaction 10.66
- USING DNA MOLECULES WITH PROTRUDING 5'-PHOSPHATE TERMINI AS TEMPLATES 10.66

**References 10.68**

**11**

**Synthetic Oligonucleotide Probes**

**Types and Uses of Oligonucleotide Probes 11.3**

- SINGLE OLIGONUCLEOTIDES OF DEFINED SEQUENCE 11.4
- POOLS OF SHORT OLIGONUCLEOTIDES WHOSE SEQUENCES ARE HIGHLY DEGENERATE 11.5

<i>The Effects of Length and Degeneracy of the Oligonucleotide on the Specificity of Hybridization</i>	11.7
<i>Designing Degenerate Pools of Short Oligonucleotides</i>	11.9
<b>POOLS OF LONGER OLIGONUCLEOTIDES OF LESSER DEGENERACY</b>	11.11
Guessers	11.11
DESIGNING A GUESSMER	11.11
LABELING OF GUESSMERS	11.15
Oligonucleotides That Contain a Neutral Base at Positions of Degeneracy	11.17

<b>Purification and Radiolabeling of Synthetic Oligonucleotides</b>	11.20
PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES	11.21
Preparation of Synthetic Oligonucleotides	11.21
Recovery of Synthetic Oligonucleotides by Electrophoresis Through a Denaturing Polyacrylamide Gel	11.23
Isolation of Oligonucleotides by Reversed-phase Chromatography on a Silica Gel	11.29

<b>LABELING OF SYNTHETIC OLIGONUCLEOTIDES BY PHOSPHORYLATION WITH BACTERIOPHAGE T4 POLYNUCLEOTIDE KINASE</b>	11.31
PURIFICATION OF RADIOLABELED SYNTHETIC OLIGONUCLEOTIDES	11.33
Purification of Radiolabeled Oligonucleotides by Precipitation with Ethanol	11.34
Purification of Radiolabeled Oligonucleotides by Precipitation with Cetylpyridinium Bromide	11.35
Purification of Radiolabeled Oligonucleotides by Chromatography Through Bio-Gel P-60	11.37
Purification of Radiolabeled Oligonucleotides by Chromatography on a Sep-Pak C <sub>18</sub> Column	11.39

<b>LABELING OF SYNTHETIC OLIGONUCLEOTIDES USING THE KLENOW FRAGMENT OF E. coli DNA POLYMERASE I</b>	11.40
---	-------

<b>Conditions for Hybridization of Oligonucleotide Probes</b>	11.45
CALCULATING MELTING TEMPERATURES FOR PERFECTLY MATCHED HYBRIDS BETWEEN OLIGONUCLEOTIDES AND THEIR TARGET SEQUENCES	11.46

<b>ESTIMATING THE EFFECTS OF MISMATCHES</b>	11.47
---	-------

<b>HYBRIDIZATION OF POOLS OF OLIGONUCLEOTIDES</b>	11.48
Preparation and Use of Solvents Containing Quaternary Alkylammonium Salts	11.50

<b>HYBRIDIZATION OF GUESSMERS</b>	11.52
HYBRIDIZATION OF OLIGONUCLEOTIDES THAT CONTAIN A NEUTRAL BASE AT POSITIONS OF DEGENERACY	11.54

<b>EMPIRICAL DETERMINATION OF MELTING TEMPERATURE</b>	11.55
---	-------

<b>References</b>	11.58
-------------------	-------

## Screening Expression Libraries with Antibodies and Oligonucleotides

<b>Constructing Expression Libraries in Plasmid and Bacteriophage <math>\lambda</math> Vectors</b>	12.4
--	------

<i>The Relative Advantages of Plasmid and Bacteriophage <math>\lambda</math> Expression Vectors</i>	12.4
Genomic DNA and cDNA Expression Libraries	12.6
Expression Libraries Constructed in Plasmids	12.8
Expression Libraries Constructed in Bacteriophage $\lambda$	12.10

<b>Using Antibodies in Immunological Screening</b>	12.11
--	-------

Choosing the Antibody	12.11
Purification of Antisera	12.13
Methods Used to Detect Antibodies Bound to Proteins Expressed in E. coli	12.14
Validation of Clones Isolated by Immunological Screening	12.15

<b>Immunological Screening of Expression Libraries</b>	12.16
--	-------

<b>SCREENING EXPRESSION LIBRARIES CONSTRUCTED IN BACTERIOPHAGE <math>\lambda</math> VECTORS</b>	12.16
---	-------

<b>SCREENING BACTERIAL COLONIES</b>	12.21
-------------------------------------	-------

Preparation of Colonies for Screening	12.21
---------------------------------------	-------

METHOD 1	12.21
----------	-------

METHOD 2	12.23
----------	-------

Processing Filters for Immunological Screening of Colonies	12.24
--	-------

<b>REMOVING ANTI-E. coli ANTIBODIES BY PSEUDOSCREENING</b>	12.25
PREPARATION OF E. coli LYSATES FOR ABSORPTION OF ANTI-E. coli ANTIBODIES	12.26

<b>REMOVAL OF ANTI-E. coli ANTIBODIES BY AFFINITY CHROMATOGRAPHY</b>	12.27
--	-------

<b>RADIOIODINATION OF IMMUNOGLOBULIN G</b>	12.29
--	-------

<b>Screening cDNA Libraries Constructed in Bacteriophage <math>\lambda</math> Expression Vectors with Synthetic Oligonucleotides</b>	12.30
--	-------

Preparing Radiolabeled Concatenated Probes	12.32
--	-------

Preparation of Filters for Screening with Radiolabeled Concatenated Probes	12.34
--	-------

Probing Immobilized Proteins with Radiolabeled DNA	12.36
--	-------

Preparation of Lysates Containing Fusion Proteins Encoded by Bacteriophage $\lambda$ gt11 Lysogens	12.38
--	-------

<b>References</b>	12.41
-------------------	-------

## DNA Sequencing

### Sequencing Techniques and Strategies 13.3

#### SANGER DIDEOXY-MEDIATED CHAIN-TERMINATION METHOD 13.6

Reagents Used in the Sanger Method of DNA Sequencing 13.6

PRIMERS 13.6

TEMPLATES 13.7

DNA POLYMERASES 13.7

RADIO-LABELLED dNTPs 13.9

ANALOGS OF dNTPs 13.10

#### MAXAM-GILBERT CHEMICAL DEGRADATION OF DNA METHOD 13.11

##### SEQUENCING STRATEGIES 13.14

Confirmatory Sequencing 13.14

De Novo Sequencing 13.14

FACTORS AFFECTING THE CHOICE BETWEEN RANDOM AND DIRECTED STRATEGIES 13.18

### Random Sequencing 13.21

#### GENERATION OF A LIBRARY OF RANDOMLY OVERLAPPING CLONES 13.24

Purification and Ligation of the Target DNA 13.24

Fragmentation of the Target DNA 13.26

SONICATION 13.26

DIGESTION WITH DNASE I IN THE PRESENCE OF MANGANESE IONS 13.28

Repair and Size Selection of DNA 13.30

Preparation of Vector DNA 13.31

Ligation to Vector DNA 13.33

### Directed Sequencing 13.34

#### GENERATION OF NESTED SETS OF DELETION MUTANTS 13.34

Generation of Nested Sets of Deletions with Exonuclease III 13.39

### Sequencing by the Sanger: Dideoxy-mediated Chain-termination Method 13.42

#### SETTING UP DIDEOXY-MEDIATED SEQUENCING REACTIONS 13.42

Preparation of Single-stranded DNA 13.42

Preparation of Primers 13.42

Microtiter Plates 13.42

Chain-extension/Chain-termination Reaction Mixtures 13.43

STOCK SOLUTIONS OF dNTPs AND ddNTPs 13.44

#### DENATURING POLYACRYLAMIDE GELS 13.45

Preparation of Buffer-gradient Polyacrylamide Gels 13.47

Loading and Running Gradient Sequencing Gels 13.54

Autography of Sequencing Gels 13.56

Reading the Sequence 13.58

### DIDEOXY-MEDIATED SEQUENCING REACTIONS USING THE KLENOW FRAGMENT OF E. coli DNA POLYMERASE I 13.59

Preparation 13.59

PREPARATION OF WORKING SOLUTIONS OF dNTPs 13.60

PREPARATION OF WORKING SOLUTIONS OF ddNTPs 13.60

Sequencing Reactions 13.61

### DIDEOXY-MEDIATED SEQUENCING REACTIONS USING SEQUENASES 13.65

Preparation 13.65

Sequencing Reactions 13.67

### SEQUENCING DENATURED DOUBLE-STRANDED DNA TEMPLATES 13.70

Sequencing of Plasmid DNAs Purified by Equilibrium Centrifugation in CsCl-Ethidium Bromide Gradients 13.71

Removal of RNA from Miniprepations of Plasmid DNA by Precipitation with Lithium Chloride 13.72

### PROBLEMS THAT ARISE WITH DIDEOXY-MEDIATED SEQUENCING 13.73

Template-specific Problems 13.73

Systematic Problems 13.73

Problems with Polyacrylamide Gels 13.74

### Sequencing by the Maxam-Gilbert Method 13.78

Asymmetric Labeling of Target DNA 13.78

Preparation of Target DNA for Maxam-Gilbert Sequencing 13.83

Reagents, Solutions, and Apparatuses 13.83

### THE TRADITIONAL METHOD OF MAXAM-GILBERT SEQUENCING 13.88

Cleavage at G residues 13.88

Cleavage at Purine Residues (A + G) 13.90

Cleavage at Pyrimidine Residues (C + T) 13.91

Cleavage at C Residues 13.92

Cleavage at A and C Residues (A > C) 13.93

Treatment of Samples with Piperidine 13.94

### ALTERNATIVE METHODS OF MAXAM-GILBERT SEQUENCING 13.95

#### TROUBLESHOOTING GUIDE FOR MAXAM-GILBERT SEQUENCING 13.95

Reading Sequencing Gels 13.95

Problems Commonly Encountered 13.95

### References 13.102

## 14

## In Vitro Amplification of DNA by the Polymerase Chain Reaction

### APPLICATIONS OF PCR AMPLIFICATION 14.5

Generation of Specific Sequences of Cloned Double-stranded DNA for Use as Probes 14.6

Generation of Probes Specific for Uncioned Genes by Selective Amplification of Particular Segments of cDNA	14.7
Generation of Libraries of cDNA from Small Amounts of mRNA	14.9
Analysis of Large Amounts of DNA for Sequencing	14.10
Analysis of Mutations	14.11
Chromosome Crawling	14.12

#### AMPLIFICATION METHODS 14.14

Precautions	14.14
Components of the Polymerase Chain Reaction	14.15

OLIGONUCLEOTIDES	14.15
BUFFERS USED FOR POLYMERASE CHAIN REACTIONS	14.15
Taq DNA POLYMERASE	14.16
DEOXYRIBONUCLEOSIDE TRIPHOSPHATES	14.16
TARGET SEQUENCES	14.16

#### Amplification Reactions 14.18

Amplification of DNA Generated by Reverse Transcription of mRNA	14.20
---	-------

#### SEQUENCING AMPLIFIED DNA BY THE SANGER DIDEOXY-MEDIATED CHAIN-TERMINATION METHOD 14.22

Protocol I: Sequencing Amplified DNA with Radiolabeled Oligonucleotide Primers	14.22
--	-------

REMOVAL OF OLIGONUCLEOTIDES AND EXCESS dNTPs FROM AMPLIFIED DNA BY SPIN DIALYSIS	14.22
RADIOLABELING OF THE OLIGONUCLEOTIDE SEQUENCING PRIMER	14.25
ANNEALING	14.26

Protocol II: Sequencing Single-stranded DNA Templates Generated by Asymmetric Amplification	14.28
---	-------

#### QUANTITATION OF INITIAL CONCENTRATION OF TARGET SEQUENCES 14.30

#### References 14.34

## Site-directed Mutagenesis of Cloned DNA

#### Generation of Deletions and Insertions 15.3

##### SIMPLE DELETIONS OR INSERTIONS 15.3

##### SYSTEMATIC DELETIONS AND INSERTIONS 15.5

Linker-insertion Mutagenesis	15.5
GENERATION OF LINKER-INSERTION MUTANTS WITH FREQUENTLY CUTTING RESTRICTION ENZYMES	15.8

##### Generation of Nested Sets of Deletion Mutants 15.14

GENERATION OF BIDIRECTIONAL SETS OF DELETION MUTANTS BY DIGESTION WITH NUCLEASE BAL 31	15.20
CLEAVAGE OF DOUBLE-STRANDED CLOSED CIRCULAR DNA WITH PANCREATIC DNase I IN THE PRESENCE OF Mg <sup>++</sup>	15.27

##### Linker-scanning Mutagenesis 15.32

ISOLATION OF TARGET FRAGMENTS CONTAINING A BglII LINKER AND A <i>kan<sup>r</sup></i> GENE	15.37
RECOVERY OF THE TARGET DNA FRAGMENT	15.47
EXCISION OF THE TARGET DNA	15.48
ANALYSIS OF CLONES THAT CONTAIN A BglII LINKER IN THE TARGET REGION	15.50

#### Oligonucleotide-mediated Mutagenesis 15.51

Preparation of Single-stranded Target DNA	15.53
Design and Selection of Mutagenic Oligonucleotides	15.54
Hybridization of Oligonucleotides to the Template DNA and Primer Extension	15.58
Transfection of <i>E. coli</i> and Screening for Mutants	15.59
Recovery of the Mutated Fragment of DNA	15.60
Methods to Improve the Efficiency of Oligonucleotide-mediated Mutagenesis	15.61

#### OLIGONUCLEOTIDE-MEDIATED MUTAGENESIS BY THE DOUBLE PRIMER METHOD 15.63

SCREENING BACTERIOPHAGE M13 PLAQUES AND COLONIES BY HYBRIDIZATION TO RADIOLABELED OLIGONUCLEOTIDES	15.66
Radiolabeling of Oligonucleotides by Phosphorylation	15.66
Screening Bacteriophage M13 Plaques by Hybridization to Radiolabeled Oligonucleotides	15.68
Screening Bacterial Colonies by Hybridization to Radiolabeled Oligonucleotides	15.72

#### OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS BY SELECTION AGAINST TEMPLATE STRANDS THAT CONTAIN URACIL (KUNKEL METHOD) 15.74

Preparation of Uracil-containing Single-stranded DNA	15.76
--	-------

#### SOLVING PROBLEMS THAT ARISE IN OLIGONUCLEOTIDE-MEDIATED, SITE-DIRECTED MUTAGENESIS 15.80

#### Using Mutagenesis to Study Proteins 15.81

##### INSERTION OF HEXAMERIC LINKERS INTO PROTEIN-CODING SEQUENCES 15.85

Designing the Hexameric Linker	15.86
Insertion of Hexameric Linkers	15.88

##### CREATING MANY MUTATIONS IN A DEFINED SEGMENT OF DNA 15.95

Use of Degenerate Pools of Mutagenic Oligonucleotides	15.96
Treatment of Double-stranded DNA with Chemical Mutagens	15.105
Treatment of Single-stranded DNA with Sodium Bisulfite	15.106
Treatment of Single-stranded DNA with Chemicals That Damage All Four Bases	15.107
Miscorporation of Nucleotides by DNA Polymerases	15.108

#### References 15.109



## Expression of Cloned Genes in Cultured Mammalian Cells

- Expression of Proteins* 16.3
- EXPRESSION OF PROTEINS FROM CLONED GENES 16.3
- FUNCTIONAL COMPONENTS OF MAMMALIAN EXPRESSION VECTORS 16.5
- Prokaryotic Plasmid Sequences That Facilitate the Construction, Propagation, and Amplification of the Recombinant Vector Sequences in Bacteria* 16.5
- A Eukaryotic Expression Module That Contains All of the Elements Required for the Expression of Foreign DNA Sequences in Eukaryotic Cells* 16.5
- PROMOTER AND ENHANCER ELEMENTS 16.6
- TERMINATION AND POLYADENYLATION SIGNALS 16.6
- SPICING SIGNALS 16.7
- ELEMENTS FOR REPLICATION AND SELECTION 16.8
- Foreign DNA Sequences 16.15
- VECTOR SYSTEMS 16.17
- Plasmid-based Vectors That Do Not Carry a Eukaryotic Replicon* 16.17
- Plasmid DNA Expression Vectors Containing Regulatory Elements from Eukaryotic Viruses* 16.17
- SIMIAN VIRUS 40 VECTORS 16.17
- BOVINE PAPILLOMAVIRUS VECTORS 16.23
- ERSTEIN-BARR VIRUS VECTORS 16.26
- Amplification Systems 16.28

### Introduction of Recombinant Vectors into Mammalian Cells 16.30

- TRANSFECTION OF COPRECIPITATES OF CALCIUM PHOSPHATE AND DNA 16.32
- Standard Protocol for Calcium Phosphate-mediated Transfection of Adherent Cells 16.33
- Calcium Phosphate-mediated Transfection of Adherent Cells in Suspension 16.37
- Calcium Phosphate-mediated Transfection of Cells Growing in Suspension Modified Calcium Phosphate-mediated Transfection Procedure 16.39
- TRANSFECTION MEDIATED BY DEAE-DEXTRAN 16.41
- Transfection Using DEAE-Dextran: Protocol I 16.42
- Transfection Using DEAE-Dextran: Protocol II 16.45
- DNA TRANSFECTION USING POLYBRENE 16.47
- DNA TRANSFECTION BY PROTOPLAST FUSION 16.48
- Preparation of Protoplasts 16.49
- Fusion of Protoplasts to Adherent Mammalian Cells 16.50
- Fusion of Protoplasts to Mammalian Cells Growing in Suspension 16.52
- DNA TRANSFECTION BY ELECTROPORATION 16.54

### Strategies for Studying Gene Regulation 16.56

- VECTORS CARRYING REPORTER GENES 16.57
- ASSAYS FOR CHLORAMPHENICOL ACETYLTRANSFERASE AND  $\beta$ -GALACTOSIDASE ACTIVITIES 16.59
- Preparation of Extracts* 16.59
- Assays for Chloramphenicol Acetyltransferase* 16.60
- METHOD 1: THIN-LAYER CHROMATOGRAPHY 16.60
- METHOD 2: EXTRACTION WITH ORGANIC SOLVENTS 16.63
- METHOD 3: DIFFUSION OF REACTION PRODUCTS INTO SCINTILLATION FLUID 16.64
- Assay for  $\beta$ -Galactosidase in Extracts of Mammalian Cells* 16.66

### Cloning by Expression in Mammalian Cells 16.68

- Cloning by Expression of cDNA Clones* 16.69
- Expression Cloning of Genomic DNA* 16.70

### References 16.73

## 17

## Expression of Cloned Genes in Escherichia coli

### Production of Fusion Proteins 17.3

- Vector Systems for the Expression of lacZ Fusion Genes* 17.3
- Construction of pUR-cDNA Plasmids and Detection of Fusion Proteins* 17.7
- Preparation of Fusion Proteins for Antibody Production* 17.8

### Production of Intact Native Proteins 17.9

#### EXPRESSION OF PROKARYOTIC GENES: PROMOTERS 17.11

- The Bacteriophage  $\lambda$  pL Promoter* 17.11
- The trp-lac Promoter* 17.13
- The Bacteriophage T7 Promoter* 17.15

#### EXPRESSION OF EUKARYOTIC GENES: PROMOTERS AND RIBOSOME-BINDING SITES 17.17

- Preparation of a DNA Fragment Containing a Functional Ribosome-binding Site* 17.18
- SYNTHESIS OF DNA ENCODING THE AMINO TERMINUS* 17.18
- PRIMER REPAIR* 17.18
- ENGINEERING A RESTRICTION SITE* 17.20
- Expression of a Gene from the Prepared Fragments* 17.24

#### ALTERNATIVE EXPRESSION SYSTEMS 17.27

- Expression of a Cloned Gene as Part of a Fusion Protein That Can Be Cleaved by a Protease or Cyanogen Bromide* 17.27
- PRODUCTION OF HYBRID PROTEINS THAT CAN BE CLEAVED WITH FACTOR X* 17.28
- Expression of Secreted Foreign Proteins* 17.31
- phoA-MEDIATED EXPRESSION AND SECRETION* 17.32

QUANTITATING THE LEVELS OF EXPRESSION OF CLONED GENES	17.33
Monitoring Expression by $\beta$ -Galactosidase Activity	17.34
INCREASING EXPRESSION OF CLONED GENES	17.35
PROTEIN PURIFICATION	17.36
Inclusion Bodies	17.36
Solubilization of Inclusion Bodies	17.37
References	17.40

## 18

### Detection and Analysis of Proteins Expressed from Cloned Genes

Production of Antibodies	18.3
Factors Affecting Immune Response	18.3
SPECIES OF ANIMAL	18.3
GENETIC FACTORS	18.4
PHYSICAL STATE OF THE ANTIGEN	18.4
AMOUNT OF ANTIGEN	18.4
ROUTE OF INJECTION	18.5
IMMUNIZATION SCHEDULES	18.5
Immunizing with Small Amounts of Antigen	18.6
Monoclonal Antibodies	18.7
Raising Antisera Against Synthetic Peptides	18.7
COUPLING OF SYNTHETIC PEPTIDES TO KEYHOLE LIMPET HEMOCYANIN	18.8
Collection and Storage of Antisera	18.10
Purification of Antibodies	18.11
PURIFICATION OF ANTIBODIES BY ADSORPTION TO PROTEIN A	18.12
PURIFICATION OF ANTIBODIES BY ABSORPTION	18.14
Removal of Cross-reacting Antibodies from Antisera	18.15
Purification of Immunospecific Antibodies	18.16
AFFINITY PURIFICATION OF MONOSPECIFIC ANTIBODIES USING ANTIGEN IMMOBILIZED ON NITROCELLULOSE FILTERS	18.17
Immunological Assays	18.19
SOLID-PHASE RADIOIMMUNOASSAY	18.19
Solid-phase Radioimmunoassays Using Two Antibodies	18.21
Iodination of Antibodies	18.24
RADIOIODINATION OF ANTIBODIES USING THE CHLORAMINE-T METHOD	18.24
IMMUNOPRECIPITATION	18.26
Radiolabeling the Target Protein	18.26
RADIOLABELING MAMMALIAN CELLS WITH [ $^{35}$ S]METHIONINE AND [ $^3$ H]CYSTEINE	18.27

METABOLIC RADIOLABELING OF PROTEINS EXPRESSED IN YEASTS AND BACTERIA	18.29
Lysis of Cells	18.30
LYSIS OF CULTURED MAMMALIAN CELLS	18.34
MECHANICAL LYSIS OF YEAST	18.35
ENZYMATIC LYSIS OF YEAST	18.36
RAPID LYSIS OF YEAST CELLS	18.38
LYSIS OF BACTERIA	18.40
Formation of Antigen-Antibody Complexes	18.42
PRECLEARING THE CELL LYSATE	18.43
Immunoprecipitation of the Target Protein	18.44
SDS-Polyacrylamide Gel Electrophoresis of Proteins	18.47
PREPARATION OF SDS-POLYACRYLAMIDE GELS	18.49
POURING SDS-POLYACRYLAMIDE GELS	18.51
STAINING SDS-POLYACRYLAMIDE GELS WITH COOMASSIE BRILLIANT BLUE	18.55
STAINING SDS-POLYACRYLAMIDE GELS WITH SILVER SALTS	18.56
DYING SDS-POLYACRYLAMIDE GELS	18.58
TRANSFER OF PROTEINS FROM SDS-POLYACRYLAMIDE GELS TO SOLID SUPPORTS: IMMUNOLOGICAL DETECTION OF IMMOBILIZED PROTEINS (WESTERN BLOTTING)	18.60
Preparation and Electrophoresis of Samples	18.61
LYSIS OF MAMMALIAN CELLS AND TISSUE IN GEL-LOADING BUFFER	18.62
Transfer of Proteins from Polyacrylamide Gels to Solid Supports	18.64
Staining Proteins Immobilized on Nitrocellulose Filters	18.67
STAINING WITH PONCEAU S	18.67
STAINING WITH INDIA INK	18.68
Blocking Binding Sites for Immunoglobulins on the Nitrocellulose Filter	18.69
Binding of the Primary Antibody to the Target Protein	18.70
INCUBATING THE NITROCELLULOSE FILTER WITH THE PRIMARY ANTIBODY DIRECTED AGAINST THE TARGET PROTEIN	18.70
INCUBATING THE NITROCELLULOSE FILTER WITH THE SECONDARY IMMUNOLOGICAL REAGENT	18.72
USE OF CHROMOGENIC SUBSTRATES WITH ENZYME-COUPLED ANTIBODIES	18.74
Translation of mRNAs	18.76
TRANSLATION OF HYBRIDIZATION-SELECTED RNA IN RETICULOCYTE LYSATES	18.76
Preparation of Rabbit Reticulocyte Lysate	18.77
Translation of Reticulocyte Lysates	18.79
TRANSLATION OF SYNTHETIC mRNAs IN VITRO	18.81
Synthesis of Synthetic mRNAs	18.82
Translation of Synthetic mRNAs	18.85
References	18.86

## Appendices

### Appendix A: Bacterial Media, Antibiotics, and Bacterial Strains

- LIQUID MEDIA A.1
  - LB Medium (Luria-Bertani medium) A.1
  - NZCYM Medium A.1
  - NZYM Medium A.1
  - YT Medium A.2
  - Terrific Broth A.2
  - SOB Medium A.2
  - SOC Medium A.2
  - M9 Minimal Medium A.3
- MEDIA CONTAINING AGAR OR AGAROSE A.4
  - STORAGE MEDIA A.5
    - Slab Cultures A.5
    - Cultures Containing Glycerol A.5
  - BACTERIAL CULTURES GROWING IN LIQUID MEDIA A.5
  - BACTERIAL CULTURES GROWING ON AGAR PLATES A.5
- ANTIBIOTICS A.6
  - SOLUTIONS FOR WORKING WITH BACTERIOPHAGE A.7
    - Maltose A.7
    - SM A.7
    - TM A.7
    - $\lambda$  Diluent A.7
  - BACTERIAL STRAIN LIST A.9

### Appendix B: Preparation of Reagents and Buffers Used in Molecular Cloning

- CONCENTRATIONS OF ACIDS AND BASES B.1
  - pK<sub>a</sub>'s of Commonly Used Buffers B.1
  - Preparation of Tris Buffers of Various pH Values B.1
  - Concentrations of Acids and Bases: Common Commercial Strengths B.2
  - Approximate pH Values for Various Concentrations of Stock Solutions B.3
- PREPARATION OF ORGANIC REAGENTS B.4
  - Phenol B.4
  - EQUILIBRATION OF PHENOL B.4
  - PHENOL-CHLOROFORM:ISOAMYLALCOHOL (25:24:1) B.5
- ATOMIC WEIGHTS B.6
  - Isotopic Data B.6
- STOCK SOLUTIONS B.9
- ENZYMES B.13
  - Proteolytic Enzymes B.13
  - Lysozyme B.13

xxx Contents

- RNAase That Is Free of DNAase B.13
- DNAase That Is Free of RNAase B.13
- AFFINITY CHROMATOGRAPHY ON AGAROSE 5'-(4-AMINOPHENYL)PHOSPHORYL URIDINE-2(3')-PHOSPHATE B.13
- ADSORPTION TO MACALOID B.14
- HEATING IN THE PRESENCE OF IODOACETATE B.15
- COMMONLY USED BUFFERS B.16

### Appendix C: Properties of Nucleic Acids

- VITAL STATISTICS OF DNA C.1
  - B Form of DNA C.1
  - Haploid DNA Content of Various Organisms C.2
  - Relationship Between Length of DNA and Its Molecular Weight C.2
  - Molarity of DNA in Solution C.3
- PURINES AND PYRIMIDINES C.3
  - Numbering of Atoms C.3
  - Adenine and Related Compounds C.4
  - Cytosine and Related Compounds C.6
  - Guanine and Related Compounds C.8
  - Thymine and Related Compounds C.10
  - Uracil and Related Compounds C.11
  - Unusual Bases C.12
  - Nucleoside Analogs Used as Chain Terminators in DNA Sequencing C.13

### Appendix D: Codons and Amino Acids

- THE GENETIC CODE (NUCLEAR GENES) D.1
- PROKARYOTIC SUPPRESSORS OF NONSENSE MUTATIONS USED IN MOLECULAR CLONING D.1
- PROPERTIES OF AMINO ACIDS D.2
  - Classification of Amino Acids D.6

### Appendix E: Commonly Used Techniques in Molecular Cloning

- GLASSWARE AND PLASTICWARE E.1
  - Siliconizing Glassware, Plasticware, and Glass Wool E.1
- PURIFICATION OF NUCLEIC ACIDS E.3
  - Extraction with Phenol-Chloroform E.3
- QUANTITATION OF DNA AND RNA E.5
  - Spectrophotometric Determination of the Amount of DNA or RNA E.5
  - Ethidium Bromide Fluorescent Quantitation of the Amount of Double-stranded DNA E.5
  - SARAN WRAP METHOD E.6
  - AGAROSE PLATE METHOD E.6
  - MINIGEL METHOD E.6
- DECONTAMINATION OF ETHIDIUM BROMIDE SOLUTIONS E.8
  - Decontamination of Concentrated Solutions of Ethidium Bromide (i.e., solutions containing >0.5 mg/ml) E.8

xxx Contents

Contents xxx

# Molecular Cloning

METHOD 1	E.8
METHOD 2	E.8
Decontamination of Dilute Solutions of Ethidium Bromide (e.g., electrophoresis buffer containing 0.5 µg/ml ethidium bromide)	E.9
METHOD 1	E.9
METHOD 2	E.9
CONCENTRATING NUCLEIC ACIDS E.10	
Precipitation with Ethanol or Isopropanol	E.10
PRECIPITATION OF DNA IN MICROFUGE TUBES	E.12
PRECIPITATION OF RNA WITH ETHANOL	E.15
CONCENTRATING NUCLEIC ACIDS BY EXTRACTION WITH BUTANOL	E.16
Drying Down <sup>32</sup> P-labeled Nucleotides from Mixtures of Ethanol and Water	E.17
MEASUREMENT OF RADIOACTIVITY IN NUCLEIC ACIDS E.18	
Precipitation of Nucleic Acids with Trichloroacetic Acid	E.18
Adsorption to DE-81 Filters	E.19
STANDARD MARKERS FOR GEL ELECTROPHORESIS E.20	
AUTORADIOGRAPHY E.21	
Fluorography	E.24
Sensitivity of Different Autoradiographic Methods	E.25
Setting up Autoradiographs	E.26
SEPARATION OF SINGLE-STRANDED AND DOUBLE-STRANDED DNA BY HYDROXYAPATITE CHROMATOGRAPHY E.30	
GEL-FILTRATION CHROMATOGRAPHY E.35	
Preparation of Sephadex	E.35
Column Chromatography	E.36
SPUN-COLUMN CHROMATOGRAPHY E.37	
PREPARATION OF DIALYSIS TUBING E.39	
Appendix F: Subcloning	
FILLING RECESSED 3' TERMINI	F.2
REMOVING PROTRUDING 3' TERMINI	F.4
RAPID CLONING IN PLASMID VECTORS	F.6
ADDITION OF LINKERS TO BLUNT-ENDED DNA F.8	
Enzymatic Phosphorylation of Nonphosphorylated Linkers	F.8
Ligation of Phosphorylated Linkers to Blunt-ended Target Fragments	F.9
Appendix G: List of Suppliers	
References	

## Index

Index Contents

## ALTERNATIVE EXPRESSION SYSTEMS

In some cases, the methods described above do not result in the production of the desired protein. In particular, it may be important that the protein not have an amino-terminal methionine, which is coded for by the ATG in these vectors. The amino-terminal methionine is removed in *E. coli* to different extents for different proteins. Another common problem is that some proteins produced intracellularly are inactive, perhaps due to incorrect folding. Some foreign proteins are degraded by intracellular proteases. Two other expression systems may solve some of these problems.


### Expression of a Cloned Gene as Part of a Fusion Protein That Can Be Cleaved by a Protease or Cyanogen Bromide

The cloned gene can be expressed as part of a fusion protein composed of a prokaryotic amino terminus connected to the protein of interest by a sequence that can be cleaved by a protease or by cyanogen bromide (Itakura et al. 1977; Goeddel et al. 1979; Nagai and Thøgersen 1984; Sung et al. 1986). The fusion protein is often stable compared to the foreign protein, and a protein can be made that does not contain an amino-terminal methionine. Nagai and Thøgersen (1984) have developed a vector designed to produce hybrid proteins that can be cleaved with the blood coagulation factor  $X_2$  to liberate the foreign protein. Factor  $X_2$  cleaves specifically after the arginine of the tetrapeptide Ile-Glu-Gly-Arg, which connects the 31 amino-terminal residues of the bacteriophage  $\lambda$  cII protein to the protein of interest (Figure 17.10).

Other proteases have been similarly employed. For example, Jia et al. (1987) used  $\lambda$ gt11 to make a  $\beta$ -galactosidase-carbohydrate-binding protein 35 (CBP35) fusion protein, which was then cleaved with V8 protease to release CBP35.

Proinsulin is readily degraded in *E. coli*. However, expression of a fusion protein composed of two molecules of proinsulin has been shown to stabilize the protein, perhaps because the protein product is larger than proinsulin. This fusion protein can then be cleaved by cyanogen bromide (Shen 1984).

In each case, it is important that the target amino acids for the protease or cyanogen bromide (which cleaves after methionine residues) does not occur at other locations within the protein of interest.



**FIGURE 17.10** M13mp11 FX is an M13mp11 derivative that has the polylinking site oriented with *EcoRI* adjacent to *lacZ'*. DNA encoding the recognition sequence for blood coagulation factor  $X_2$  (Ile Glu Gly Arg shown in bold) is cloned into the *Bam*HI site. Any coding sequence with blunt ends can be cloned into the *Sal*I site to place the FX<sub>2</sub> cleavage site adjacent to the desired protein sequence. The entire DNA sequence can then be inserted into an appropriate expression vector (e.g., pLcII) (Nagai and Thøgersen 1984).

The scope of recombinant DNA research has undergone a dramatic expansion. In its early days, the field was concerned mainly with describing the structure of eukaryotic cDNAs, establishing the topography of the corresponding genomic sequences, and defining the location of controlling elements. Although this kind of cataloging remains an essential part of molecular cloning, the field has now broadened to include expression of cloned genes and analysis of the proteins they encode. Methods commonly used to express cloned genes in prokaryotic and eukaryotic systems are discussed elsewhere in this manual. In this chapter, we describe techniques to detect and quantitate foreign proteins synthesized in these systems. Although we emphasize methods to analyze proteins expressed in mammalian cells, the same techniques are applicable to proteins synthesized in yeast and prokaryotic systems. We also describe methods to synthesize proteins *in vitro* using the rabbit reticulocyte system and natural mRNAs or synthetic RNAs.

Proteins synthesized in heterologous systems can be detected either by assaying for a particular biological activity or by employing assays that are independent of such activity. In a few cases, the protein of interest carries an enzymatic or other biological activity (e.g., the ability to bind a specific ligand) that can be assayed in intact cells or in extracts *in vitro*. Although such assays can be extremely useful, they frequently suffer from one of several practical limitations: (1) They may not be sufficiently sensitive to detect the small amounts of protein that are synthesized in small-scale mammalian cultures. (2) The host cells may themselves express an endogenous protein that either displays the same biological activity as the foreign protein or interferes with it. (3) The detection of biological activity in an extract says nothing about the specific activity of the protein of interest (i.e., the activity displayed by a given amount of the protein). This point becomes especially important when measuring the activity of mutated forms of the protein that have been generated by *in vitro* mutagenesis or when expressing the wild-type protein in heterologous cells that may not allow the protein to fold correctly or may not carry out the correct posttranslational modifications. For these and other reasons, it is essential to develop assays that are independent of biological activity and sensitive enough to measure very small amounts of the protein. The reagents of choice for these assays are antibodies that react specifically with the foreign protein.

## Production of Antibodies

It is important to bear in mind from the outset that antibodies that react specifically with the foreign protein fall into three general classes:

- *Antibodies that react with the foreign protein independently of its conformation.* Antibodies of this type are particularly useful for measuring the total amount of the target protein present in crude preparations or cell extracts. They are usually raised by immunizing animals with partially denatured protein or with a peptide whose sequence corresponds to part of the intact protein. However, monoclonal antibodies that are pan-specific are not uncommon.
- *Antibodies that react only with epitopes specific to the native form of the target protein.* Antibodies of this type are typically monoclonal and recognize a given sequence of amino acids only when it occurs in the particular three-dimensional conformation that is characteristic of the native form of the target protein.
- *Antibodies that react only with denatured forms of the protein.* These are raised against fully denatured antigens and can be either monoclonal or polyclonal.

## Factors Affecting Immune Response

Although there is no way to guarantee the production of particular types of antibodies, it is advisable to choose an immunization regimen that will favor antibodies with the desired characteristics. It is then necessary to screen several independent antisera or a series of monoclonal antibodies to identify those best suited to the tasks at hand. A number of factors that affect the strength and specificity of the immune response should be considered by workers planning to raise antisera. These are described below.

### SPECIES OF ANIMAL

To raise antisera that react with as many potential epitopes as possible, choose a species of animal that is phylogenetically different from the species from which the target protein was isolated. Inoculation of a native protein into an animal of the same species is likely to yield antibodies directed only against minor epitopes that vary from individual to individual. For most proteins, rabbits are the animals of choice: They are easy to bleed, yielding several milliliters of serum; they are sufficiently robust to withstand multiple bleedings; and they are reasonably inexpensive. Chickens have many of the same virtues; however, they are clearly a second choice because their antibodies, unlike those of rabbits, do not bind to protein A of *Staphylococcus aureus*. Mice and guinea pigs are less desirable because their small size makes repeated drawing of blood difficult.

## GENETIC FACTORS

Outbred animals are preferred to inbred strains, which may be genetically incapable of responding vigorously to certain antigens. Even outbred animals, however, exhibit a broad range of intensity of response to the same immunogen. It is therefore essential to immunize several animals, especially when attempting to raise antisera against poor immunogens. In some cases, it is possible to improve the response to such antigens by physically coupling them to a carrier protein such as keyhole limpet hemocyanin (KLH) or bovine serum albumin.

## PHYSICAL STATE OF THE ANTIGEN

Aggregated protein is a much better immunogen than soluble, dispersed protein. Partial denaturation may help to increase immunogenicity but may yield antisera that fail to react with native protein. Severely denatured proteins (e.g., proteins that have been extensively boiled, reduced, and alkylated) often yield antisera that react exclusively or preferentially with denatured protein. Many immunology textbooks state that denatured proteins are poor antigens. This is a fallacy that almost certainly stems from the failure to assay the antisera against the appropriately denatured form of the antigen.

When the amount of antigen is limiting, adjuvants are used to enhance the immune response. These substances prolong the half-life of the antigen by protecting it from degradation. In addition, they minimize any direct toxic effects of the antigen and, by allowing a slow, sustained release from the site of immunization, increase the efficiency of uptake of the antigen by macrophages. A large variety of substances can be used as adjuvants, including alum, mineral oils, charcoal, and Freund's adjuvant (complete or incomplete). Nitrocellulose filters and polyacrylamide are particularly useful adjuvants when only small amounts of antigen are available. Bands of polyacrylamide containing specific polypeptides can be excised from polyacrylamide gels or electrophoretically transferred to nitrocellulose filters and used directly for immunization (see discussion below on immunizing with small amounts of antigen).

*Note:* If the antisera will be used to detect proteins expressed in *E. coli*, Freund's adjuvant should not be used due to the presence of bacterial components in the Freund's adjuvant that will generate cross-reactive antibodies to *E. coli* proteins.

## AMOUNT OF ANTIGEN

Injection of large amounts of a soluble immunogen can lead to the establishment of a tolerant state. Although the use of adjuvants greatly reduces the chances that tolerance will be induced, it is important not to use more antigen than necessary, since this often leads to the generation of antisera of low avidity. Although there is no foolproof method to predict what the lowest effective dose of an unknown antigen will be, the immunization regimens described below usually yield antisera of high titer and avidity. If sufficient animals and antigen are available, it is best to inoculate batches of animals with different amounts of antigen. Those that receive too little antigen to

elicit a response can always be given a larger dose subsequently. Booster injections are essential to obtain antisera of high titer and avidity. The first of these booster injections should be given when the primary response is past its peak (about 4–6 weeks after the primary injection of antigen in the case of rabbits). About 7–10 days after the first booster injection, test bleeds should be taken, and further booster injections should be given at regular intervals to those animals that show the maximum response to the antigen. The length of these intervals varies from antigen to antigen and cannot be predicted in advance. The best procedure is to boost the animal when the titer of circulating antibody begins to drop. The amount of antigen used for boosting is usually two- to threefold less than that used for primary immunization. Such booster injections are usually given to rabbits by the same route (although not necessarily at the same site) as the primary immunization. However, mice are more frequently boosted by intravenous injection of soluble antigen even if the primary immunization was by another route.

## ROUTE OF INJECTION

Antigens stimulate the strongest immune responses when they are injected directly into the animal's popliteal lymph nodes. However, this requires special skill, and the much simpler methods of injection of antigen mixed with adjuvant into multiple intradermal or subcutaneous sites or into a single intramuscular site are used more commonly. In multiple intradermal injections, where the antigen-adjuvant complex is injected at 20–40 sites spread over the body of the animal, the primary response is produced faster and the titer of antibody is generally higher than when the antigen is injected into a single intramuscular site. Furthermore, fewer booster injections are required. However, since an ulcer forms at the site of each injection of adjuvant, the multiple-injection method may cause more distress to the animal.

## IMMUNIZATION SCHEDULES

The injection of antigen should be carried out by someone experienced in handling animals according to the procedures approved by your animal care facility. Some facilities prefer not to use certain types of adjuvants (e.g., Freund's complete adjuvant or crushed polyacrylamide gels), and it is therefore important to agree on an immunization regimen before animals are ordered. *Make sure that a sample of blood is drawn from each animal before immunization is begun.* Although the immunization schedule will vary according to the nature of the antigen, the amount of antigen available, and its immunogenicity, a reasonable general plan for raising antisera against an antigen that is readily available is described below.

### Rabbits

Dissolve 100  $\mu$ g of antigen in 0.5 ml of a buffer in which the antigen is soluble, and emulsify the solution with an equal volume of Freund's complete adjuvant. Use the emulsion immediately. An emulsion of the desired consistency is readily obtained by passing the solution through a double-canula microemulsifying needle (Thomas Scientific 345OD46).

• **For intramuscular injection:** Inject 0.5 ml of emulsified antigen-adjutant into each of two limbs of the animal. Four to 6 weeks later, inject 0.25 ml of freshly prepared emulsion into another limb. Limbs should be used in rotation every 4–6 weeks for subsequent booster injections.

• **For intradermal injection:** Inject 0.025 ml of emulsified antigen at 24–36 sites distributed over the back of a shaved rabbit. Four to 6 weeks later, boost the animal by intramuscular injection of 0.25 ml of freshly prepared emulsified antigen-adjutant into each of two limbs of the animal.

Arrange for blood (20–40 ml) to be drawn 7–10 days after each booster injection. The serum should be tested for the presence of antibody by one of the standard methods, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), or immunoprecipitation. Animals that respond poorly to the antigen after two booster immunizations should be sacrificed. Responsive animals should be boosted at regular intervals (2–3 months) until a high titer of antibody is attained. Blood (40 ml) can then be drawn weekly until the titer drops. The animal should then be allowed to rest for 2–3 months and reboosted before bleeding is resumed.

#### Mice

Dissolve 20–50  $\mu$ g of antigen in 100  $\mu$ l of a buffer in which the antigen is soluble, and emulsify the solution with an equal volume of Freund's complete adjuvant. Use the emulsion immediately. Inject 50  $\mu$ l of the emulsified antigen-adjutant subcutaneously at each of four sites. Four to 6 weeks later, boost the mice with an intraperitoneal injection of 100  $\mu$ l of the appropriate buffer containing 5–10  $\mu$ g of soluble antigen. The mice should be bled from the median tail vein 7–10 days after the booster injection, and the serum should be tested for the presence of antibody by one of the standard methods. The animals can be reboosted if necessary, and blood can be withdrawn every 3–4 days until the antibody titer drops.

#### Immunizing with Small Amounts of Antigen

Frequently, the molecular biologist is faced with the problem of raising antibodies to proteins that are available in extremely small amounts. To maximize the chances of obtaining an immune response, the soluble antigen (up to 10  $\mu$ g) emulsified in Freund's complete adjuvant should be injected into the popliteal lymph node of a rabbit. However, immune responses can also be obtained when animals are immunized by conventional routes with small amounts of polypeptides (100 ng to 5  $\mu$ g) that have been recovered from polyacrylamide gels. After electrophoresis, the polypeptides are transferred from the gel to a nitrocellulose filter by western blotting, and the relevant segment of the nitrocellulose filter is then either implanted subcutaneously in a rabbit or dissolved in a small volume of dimethyl sulfoxide (DMSO), mixed with Freund's complete adjuvant, and injected intradermally as described above. Alternatively, the band of polyacrylamide containing the polypeptide of interest is cut from the gel. The polyacrylamide is then broken into small fragments by freezing and thawing and passage through a narrow-gauge hypodermic needle. The fragments of gel are then emulsified in an equal volume of Freund's complete adjuvant and injected subcutaneously into mice or intradermally at many sites into a rabbit.

#### Monoclonal Antibodies

The introduction of cell hybridization to generate myeloma-like cell lines that secrete monoclonal antibodies with desired specificities has greatly expanded the range, number, and reproducibility of immunological reagents (Köhler and Milstein 1975, 1976). Although the protocols to develop hybridomas are nearly as numerous as the number of investigators using them, almost all of them involve fusing spleen cells from a hyperimmunized donor with cells from a genetically marked myeloma that has been adapted to grow in tissue culture. Mixed populations of the resulting hybrid cells are tested for their ability to secrete antibody of the desired specificity, and clones derived from individual cells are then established. In the best cases, the supernatant of the resulting cultures contains up to 50  $\mu$ g/ml of immunoglobulin. However, even greater amounts of antibody (5–20 mg/ml) can be obtained by growing the cloned hybridoma as an ascites tumor in the peritoneal cavity of mice.

Monoclonal antibodies are particularly useful when an immune reagent is required that reacts specifically with a single component in a complex mixture of antigens, for example, an enzyme that is contaminated with other proteins. Although an immunized animal may develop antibodies against all of the proteins in the mixture, an individual B lymphocyte will produce antibody specific for only one of them. The establishment of permanent cell lines from such individual B cells provides a method to obtain an antibody that is specific for the enzyme of interest. When using a monoclonal antibody, it is important to determine its subclass, using commercially available anti-idiotypic reagents, since not all subclasses of immunoglobulins bind efficiently to commonly used immunoabsorbents such as staphylococcal protein A.

A description of methods to generate monoclonal antibodies is beyond the scope of this manual. However, a number of excellent reviews are available that describe the techniques in detail (see, e.g., Campbell 1984; Goding 1986; Kipps and Herzenberg 1986; Harlow and Lane 1988).

#### Raising Antisera against Synthetic Peptides

If the amino acid sequence of the protein of interest is known or can be deduced from the corresponding nucleic acid sequence, it is possible to raise specific antisera by immunizing animals with short synthetic peptides (for review, see Lerner 1984). If the experimenter wishes to generate antibodies that react with specific sites in the target protein, there may be little or no choice in the sequence of the peptide that is used as an immunogen. However, if the antibody is to be used merely as a reagent to identify the protein, there may be an opportunity to select a sequence of amino acids that is likely to be highly immunogenic. If possible, choose a sequence of 12–15 amino acids that contains no more than four adjacent hydrophobic residues and no more than six hydrophobic residues in total—the greater the number of charged amino acids in the sequence the better. Peptides with these properties are likely to be soluble in aqueous solvents and therefore easy to couple to carrier proteins. In addition, the cognate sequence is more likely to be present on the surface of the target protein and therefore accessible to the antibody.

Usually, the synthetic peptide is coupled to a carrier protein such as



keyhole limpet hemocyanin (KLH) through an amino- or carboxy-terminal cysteine residue. Ideally, therefore, the sequence of the peptide should end with a "natural" cysteine that is present in the cognate sequence of the target protein. If this is not possible, choose a peptide that contains no cysteine at all. Chemical synthesis of the peptide, which proceeds from the carboxyl terminus to the amino terminus, is then initiated from an "artificial" cysteine that has no counterpart in the cognate sequence of the target protein. This cysteine residue is used as a linker to couple the synthetic peptide to the carrier protein.

#### COUPLING OF SYNTHETIC PEPTIDES TO KEYHOLE LIMPET HEMOCYANIN

This method, from the laboratory of M. Brown and J. Goldstein (pers. comm.), is a modification of a technique described originally by Green et al. (1982).

1. Dilute KLH with phosphate-buffered saline (pH 6.0) (PBS; see Appendix B) to a final concentration of 10 mg/ml.

KLH (Calbiochem no. 374817) is supplied at a concentration of 100 mg/ml in 50% glycerol. KLH should be stored at 4°C.

The pH of PBS is adjusted to pH 6.0 with 3 N HCl.

2. Transfer 1 ml of the KLH solution to a clean 15-ml tube. Put a small, Teflon-covered magnet in the tube, and stir the solution vigorously on a magnetic stirrer. Add 50  $\mu$ l of dimethyl sulfoxide (DMSO) containing 1.5 mg MBS *under the surface of the KLH solution*. Continue stirring for another 30 minutes.

MBS is *m*-maleimidobenzoic acid *N*-hydroxysuccinimide ester (Sigma M 8759). It was first used as a coupling agent by Liu et al. (1979).

3. Prepare a column (20-ml bed volume) of Sephadex G-25, equilibrated in PBS (pH 7.4). Apply the sample of KLH to the column and begin to collect 1-ml samples. Immediately after the void volume, a cloudy, grayish material elutes from the column; this is KLH-MBS.

The purpose of the column is to remove unconjugated MBS, DMSO, and glycerol from the sample.

If necessary, the elution profile of KLH-MBS can be monitored by measuring the OD<sub>280</sub> of the column effluent. The recovery of KLH-MBS is usually > 80%.

4. Dissolve 5 mg of the synthetic peptide in the smallest possible volume of PBS (pH 7.4). This step is best carried out as follows:

- a. Add 5 mg of the peptide to 200  $\mu$ l of PBS in a 15-ml tube. Continue to add PBS in 100- $\mu$ l aliquots until the peptide is completely dissolved or the volume of the solution is 500  $\mu$ l.
- b. If the peptide is not dissolved, add 5 N NaOH in 5- $\mu$ l portions until a total of 25  $\mu$ l has been added.
- c. If the peptide is still not dissolved, add DMSO in 100- $\mu$ l portions until a total of 500  $\mu$ l has been added.

5. Mix the KLH-MBS solution from step 3 with the dissolved peptide. *Vortex vigorously to mix the two solutions*. Stir the mixture for 1 hour at room temperature.

6. Store the solution at -20°C until it is needed for injection into animals.

#### Notes

- i. If the peptide is too hydrophobic, it will not dissolve, and alternative, less efficient ways must then be used to raise antiserum. For example, the hydrophobic peptide can be emulsified with Freund's complete adjuvant and injected without solubilization. This results in the production of specific antibodies that are often of low titer and avidity.
- ii. Upon thawing, the cross-linked peptide may form a precipitate. If so, break up the aggregates by sonication or by passage through a 22-gauge hypodermic needle. For immunization, mix approximately 300  $\mu$ g of cross-linked peptide with an equal volume of Freund's complete adjuvant and inject the emulsion into mice (subcutaneously) or rabbits (intramuscularly or intradermally) as described on pages 18.5-18.6. Two weeks later, boost the animals with a second injection. Mice should be boosted again, 1 week later, with an intraperitoneal injection of 200  $\mu$ g of peptide mixed with 4 mg of alum. Rabbits should be boosted every 6 weeks with 200  $\mu$ g of peptide mixed with 4 mg of alum. Mice should be bled 4-5 weeks after the initial injection; rabbits should be bled 1-2 weeks after the second booster injection and at regular intervals thereafter.

Blood from animals that have been fasted for several hours should be collected in sterile centrifuge tubes or bottles (without citrate or heparin) and allowed to clot at room temperature. A glass rod or sealed Pasteur pipette should then be used to "ring" the clot (i.e., to loosen the clot from the wall of the tube or bottle). During the next several hours, the clot will retract to about one half of its original volume, leaving the antiserum as a straw-colored liquid. Transfer as much as possible of the antiserum to a fresh tube, and then centrifuge the clot at 1500g for 10 minutes at room temperature. Combine the supernatant with the previously removed antiserum, discard the clot, and store the antiserum.

Antisera may be stored as a lyophilized powder at room temperature, as a solution frozen at  $-20^{\circ}\text{C}$  or  $-70^{\circ}\text{C}$ , or at  $4^{\circ}\text{C}$  in the presence of 0.02% sodium azide. Although lyophilization is preferred on theoretical grounds, it is impractical for many laboratories and unnecessary for most purposes. Some guidelines for storing antisera are listed below.

**Caution:** Sodium azide is poisonous. It should be handled with great care, wearing gloves, and solutions containing it should be clearly marked.

1. Antisera should be stored in small aliquots that are labeled with the name of the animal and the date of the bleed. Polyclonal antisera are best stored undiluted, whereas monoclonal antibodies should be stored at concentrations of  $> 1 \text{ mg/ml}$  in solutions containing  $0.1 \text{ M NaCl}$ .
2. Do not mix antisera taken from different animals or from different bleeds taken from the same animal. Individual sera can contain cross-reactive antibodies and, during a course of immunizations, an individual animal may respond to other environmental antigens that also are cross-reactive. To avoid the possibility of adulterating a batch of good antiserum with one that is less desirable, keep each bleed from each animal separate.
3. Antisera stored at  $-20^{\circ}\text{C}$  are stable for several years. However, repeated freezing and thawing of antisera causes denaturation and aggregation of immunoglobulins, with a consequent decrease in potency. Once a frozen aliquot is thawed, it should thereafter be stored at  $4^{\circ}\text{C}$ .
4. Immunoglobulins of the IgM class are far less robust than IgG and tend to denature when stored at  $-20^{\circ}\text{C}$ , which is near the eutectic point of NaCl solutions. Antisera that contain high levels of IgM directed against the target antigen should therefore be stored lyophilized or at  $-70^{\circ}\text{C}$ .
5. Antisera gradually become turbid during prolonged storage at  $4^{\circ}\text{C}$ . The precipitate, which is composed mostly of lipoproteins and other cryoproteins whose solubility is limited at  $4^{\circ}\text{C}$ , does not affect the ability of the immunoglobulins to react with their target antigens. Antisera drawn from animals that have not been fasted contain higher levels of lipoprotein and rapidly become turbid during storage at  $4^{\circ}\text{C}$ . Do not mistake this turbidity for bacterial growth. Before use, antibodies should be centrifuged briefly (at 12,000g for 2 minutes at  $4^{\circ}\text{C}$  in a microfuge) to sediment any particulate matter and to cause lipoproteins to float to the surface.

## Purification of Antibodies

For most purposes, antisera need not be fractionated before use. However, if the antisera are to be radiolabeled or conjugated to enzymes such as horseradish peroxidase (HRP) or alkaline phosphatase, it is necessary to purify the IgG fraction or, in some cases, to purify the antibody of interest by binding it to its cognate antigen.

Although many techniques have been developed to purify IgG molecules, the method of choice is adsorption to, and elution from, beads coated with protein A, a component of the cell wall of *S. aureus* (Hjelm et al. 1972). For reasons that are not known, this protein ( $M_r = 42,000$ ) binds strongly to sites in the second and third constant regions of the Fc portion of the immunoglobulin heavy chain (Deisenhofer 1981). Each IgG molecule therefore contains two binding sites for protein A. Because protein A itself has four potential sites for binding to IgG (Sjödahl 1977), it is possible to form multimeric complexes of the two types of protein.

Not all immunoglobulins bind to protein A with the same affinity. Antibodies from humans, rabbits, and guinea pigs bind most tightly, followed in decreasing order of affinity by those from pigs, mice, horses, and cows (Kronvall et al. 1970; Goudswaard et al. 1978). Immunoglobulins from goats, rats, chickens, and hamsters bind in a much weaker fashion, and a "bridging" antibody is usually required to purify them by adsorption to protein A. Within any one species, different classes of immunoglobulins vary in the sequences of their Fc regions and consequently bind to protein A with different affinities. Of the major classes of human IgG, for example, three (IgG1, 2, and 4) bind with high affinity and one (IgG3) binds very weakly, if at all. Similarly, mouse IgG2a binds with high affinity, IgG2b and IgG3 bind tolerably well, and IgG1 binds poorly (Ey et al. 1978). These differences are generally unimportant when dealing with polyclonal sera, where antibodies against the target antigen are distributed throughout all of the major subclasses of IgG. Consequently, purification of polyclonal immunoglobulins raised in rabbits, humans, and mice by binding to protein A may alter the distribution of subclasses of IgG, but it rarely changes the specificity or avidity of the final preparation. However, monoclonal antibodies secreted from hybridomas carry only one subclass of heavy chain. Before attempting to purify a given monoclonal antibody, it is essential to determine the subclass of its heavy chain, using commercially available immunological reagents directed against isotypes of the Fc region. If the monoclonal antibody falls into a class that binds poorly to protein A (e.g., human IgG3 or mouse IgG1), it should be purified by another method (e.g., ammonium sulfate precipitation followed by chromatography on DEAE-cellulose). Alternatively, a bridging antibody can be used to attach the monoclonal antibody to protein A.

## PURIFICATION OF ANTIBODIES BY ADSORPTION TO PROTEIN A

Protein A coupled to a solid support by cyanogen bromide is supplied by several manufacturers (e.g., protein A-Sepharose CL-4B; Pharmacia). Each milliliter of swollen gel can bind approximately 10–20 mg of IgG (equivalent to 1–2 ml of antiserum). Antibodies bind to protein A chiefly by hydrophobic interactions (Deisenhofer 1981) that can be disrupted at low pH. Protein A is remarkably resilient and withstands repeated cycles of exposure to low pH agents such as urea, guanidine hydrochloride, or potassium isothiocyanate without permanent damage. Most antibodies can withstand transient exposure to low pH, and this is now the standard method to release them in an active form from protein A-Sepharose beads.

The following is a modification of the method of Goudswaard et al. (1978).

1. Prepare a column of protein A-Sepharose, equilibrated in 100 mM Tris · Cl (pH 8.0) according to the manufacturer's instructions. Each milliliter of swollen gel can adsorb between 10 mg and 20 mg of pure IgG.

Protein A-Sepharose is very expensive and should be used sparingly. For the preparation of IgG for most laboratory purposes, 1-ml columns are poured and run in pasteur pipettes plugged with sterile glass wool.

2. Add 0.1 volume of 1 M Tris · Cl (pH 8.0) to the antibody preparation (serum or monoclonal antibodies derived from hybridomas grown either in tissue culture or in the peritoneal cavity of mice).

The concentration of IgG in serum obtained from healthy animals is approximately 10 mg/ml. However, the concentration of antibody in supernatants of hybridomas or in ascitic fluid is highly variable, ranging from 10 µg/ml to 100 µg/ml in the former case and from 1 mg/ml to 20 mg/ml in the latter. To determine the concentration of antibody in serum, analyze an aliquot by SDS-polyacrylamide gel electrophoresis and compare the intensity of staining of the heavy and light chains with a set of immunoglobulin standards run on the same gel. When the antibody is the dominant protein in the solution (e.g., in ascitic fluid or in the supernatant of efficiently secreting hybridomas), its approximate concentration can be estimated from the  $OD_{280}$  of the solution ( $1 OD_{280} = 0.75 \text{ mg/ml}$  of pure IgG).

3. Load the antibody preparation on the column, and then wash the column with 10 column volumes of 100 mM Tris · Cl (pH 8.0) followed by 10 volumes of 10 mM Tris · Cl (pH 8.0).

4. Add 1 column volume of 100 mM glycine (pH 3.0). Begin collecting 500-µl fractions of the column eluate in microfuge tubes containing 50 µl of 1 M Tris · Cl (pH 8.0).

5. Just as the column runs dry, add another 1 column volume of 100 mM glycine (pH 3.0) and continue collecting samples. Continue this process until 5 column volumes have eluted from the column.

6. Identify the fractions that contain IgG by measuring their absorbance at 280 nm, using elution buffer as a blank. The concentration of IgG in the column eluate should be at least 1 mg/ml (an  $OD_{280}$  of 1.33).

7. Dispense the IgG into aliquots and store them as described on page 18.10.
8. Remove residual proteins from the column by washing it sequentially with 10 volumes of 3 M urea, 1 M LiCl, and 100 mM glycine (pH 2.5). Finally, readjust the pH of the column to 8.0 by washing it with 10 volumes of 100 mM Tris · Cl (pH 8.0). Store the column at 4°C in 100 mM Tris · Cl (pH 8.0) containing 0.02% sodium azide.

**Caution:** Sodium azide is poisonous. It should be handled with great care wearing gloves, and solutions containing it should be clearly marked.

## PURIFICATION OF ANTIBODIES BY ADSORPTION

Although hyperimmune antisera raised in experimental animals contain very high concentrations of immunoglobulin directed against the target antigen, such antisera also always contain antibodies directed against other antigens. In addition, the immunoglobulins in antisera may bind with low avidity to molecules that are not true target antigens. For these and other reasons, antisera can manifest a level of background reactivity that is unacceptably high. There are three ways to deal with this problem:

- An innocuous blocking agent (e.g., bovine serum albumin or normal serum) can be used to compete with the immunoglobulin for nonspecific binding sites.
- Antibodies that are directed against specific contaminating antigens (e.g., bacterial antigens) can be removed by adsorption.
- Antibodies directed against the target antigen can be separated from contaminating antibodies by affinity purification.

Blocking agents are routinely included in solutions used, for example, in immunological screening of expression libraries constructed in plasmid or bacteriophage  $\lambda$  vectors (see Chapter 12). Methods to remove antibacterial antibodies from antisera used for such screening are described on pages 12.25–12.28. In the section that follows, we describe techniques to remove antibodies that cross-react with components in eukaryotic cells and discuss methods that are available for affinity purification of antibodies.

## Removal of Cross-reacting Antibodies from Antisera

To remove antibodies that react with antigens present in mammalian cells, use an acetone extract of a cell line or tissue that is known not to express the true target antigen. If such a cell line is not available or cannot be identified with certainty, use an acetone extract of commercially available dried yeast.

1. Resuspend the tissue or cells in 0.1 M NaCl, using 2 ml of ice-cold saline solution for every gram of tissue or cells. The suspension should be as homogeneous as possible, with no fibrous material or large clumps of cells. If necessary, filter the tissue suspension through three layers of cheese-cloth.
2. Add 4 volumes of acetone, chilled to  $-20^{\circ}\text{C}$ , and mix the suspension vigorously. Store the suspension on ice for 1 hour.
3. Centrifuge the suspension at 10,000g for 10 minutes at  $4^{\circ}\text{C}$ . Discard the supernatant, and resuspend the pellet in acetone ( $-20^{\circ}\text{C}$ ) using the same amount that was used in step 2. Vigorous vortexing may be necessary to achieve complete resuspension. Store the suspension on ice for 10 minutes.
4. Recentrifuge, and discard the supernatant. Transfer the pellet to a piece of Saran Wrap. Allow the acetone to evaporate in a chemical hood. Mix the pellet from time to time to speed evaporation.
5. When the powder is completely dry, transfer it to a container with a tight-fitting lid. Store the powder at  $-20^{\circ}\text{C}$  until needed. Each gram of tissue or cells yields approximately 100 mg of powder.
6. To remove cross-reacting antibodies from antiserum, add the powder to a final concentration of 1% (w/v). Mix the suspension carefully, taking care to avoid producing bubbles and froth, which denature proteins. Store the suspension on ice for 15 minutes. Remove the powder by centrifugation at 10,000g for 10 minutes at  $4^{\circ}\text{C}$ . Store the supernatant, which should now be free of cross-reacting antibodies, in small aliquots at  $-20^{\circ}\text{C}$ .

### Purification of Immunospecific Antibodies

Antibodies may be purified by adsorption to, and elution from, their cognate antigen. In some cases (e.g., when the antigen is a protein), the antigen may be coupled to a matrix such as cyanogen-bromide-activated Sepharose. Antibodies directed against epitopes displayed by the protein will be retained by the column; all other immunoglobulins will pass through. The bound antibody is then released from the column by agents that disrupt the antigen-antibody complex (e.g., potassium thiocyanate, low-pH buffers, etc.). Details of the methods used to prepare antibodies by immunochromatography vary from antigen to antigen and from antibody to antibody. However, the general principles are well-described in a number of reviews (see, e.g., Hurn and Chantler 1980; Harlow and Lane 1988). When using these methods, it is essential to use highly purified antigen and to avoid the batch of antigen that was used to raise the antibody in the experimental animals. Furthermore, it is important to remember that antibodies with different affinities for the antigen will show different patterns of elution from the column; those that bind loosely to the antigen will elute first, and those that bind most tightly will elute last. In fact, antibodies with the highest avidity may be denatured by the elution buffer before they dissociate from the antigen. Thus, there is a tendency during immunopurification to select for antibodies that are specific for the antigen but that bind with low affinity.

Antibodies may be purified on a small scale by adsorption to, and elution from, protein antigens that are immobilized on diazotized paper (Olmsted 1981) or nitrocellulose filters (Burke et al. 1982; Smith and Fisher 1984; Earnshaw and Rothfield 1985) after electrophoresis through SDS-polyacrylamide gels. Antibodies prepared by this method are especially useful for confirming the identity of cDNA clones isolated from expression libraries constructed in bacteriophage  $\lambda$  or plasmid expression vectors. For example, many false-positive clones can be eliminated by purifying antibodies from crude sera by virtue of their ability to bind to a fusion protein partly encoded by the cloned cDNA and testing the ability of these purified antibodies to precipitate the target protein or to react with it on a western blot. However, this method works well only when the antibodies react with epitopes that are displayed on denatured proteins. Typically, about 50 ng of immunopurified antibody are recovered per microgram of target protein loaded on the original SDS-polyacrylamide gel. Because of the idiosyncratic nature of the interactions between antibodies and their target proteins, it is not possible to give conditions for binding and elution that are universally applicable. For example, most antibodies can be eluted from their immobilized antigens with glycine buffer (pH 2.8). However, Earnshaw and Rothfield (1985) found that antibodies to human centromeric proteins could be eluted only with a solution containing 3 M potassium thiocyanate and 0.5 M  $\text{NH}_4\text{OH}$ . Anyone who wishes to use this powerful technique should therefore be prepared to invest some effort in defining the optimal conditions for binding and release of their particular antibodies from their target proteins. However, the following protocol, which is a modification of Olmsted's (1981) method produced by J. Allan and M. Douglas (pers. comm.), has worked well with a number of rabbit polyclonal antibodies directed against a variety of mammalian and yeast proteins.

### AFFINITY PURIFICATION OF MONOSPECIFIC ANTIBODIES USING ANTIGEN IMMOBILIZED ON NITROCELLULOSE FILTERS

1. Load a preparation containing the target antigen along the entire length of an SDS-polyacrylamide gel (see pages 18.47–18.54). Between 650  $\mu\text{g}$  and 1000  $\mu\text{g}$  of soluble protein can be loaded on a gel of standard size without overloading. After the gel has been run, transfer the proteins from the gel to a nitrocellulose filter as described on pages 18.64–18.66.
2. After transfer, incubate the filter in blocking buffer for 1 hour at room temperature. Use 0.25 ml of blocking buffer for each square centimeter of nitrocellulose filter.

#### Blocking buffer

3% bovine serum albumin in phosphate-buffered saline (PBS; see Appendix B) containing 0.02% sodium azide.

**Caution:** Sodium azide is poisonous. It should be handled with great care wearing gloves, and solutions containing it should be clearly marked.

The bovine serum albumin serves as a blocking agent by binding to sites on the nitrocellulose filter that are not occupied by proteins transferred from the gel.

3. Add the first antibody, and incubate for 5 hours at room temperature or for 16 hours at 4°C with gentle shaking.

The first antibody, which should react strongly with the denatured target antigen, can usually be diluted 500- to 1000-fold in the blocking buffer.

4. Discard the antibody solution, and rinse the nitrocellulose filter in 0.15 M NaCl for 20 minutes at room temperature.

5. Rinse the filter in PBS for 20 minutes at room temperature.

6. Using a sharp scalpel blade, cut a strip approximately 0.2 cm wide from each side of the filter. Transfer the strips to a petri dish, and stain them with horseradish-peroxidase (HRP)-coupled antibody directed against the first antibody (see page 18.75). Meanwhile, continue washing the main section of the nitrocellulose filter in PBS.

HRP-coupled second antibody should be used at the dilutions recommended by the manufacturer.

7. Remove the stained strips from the petri dish and align them with the main section of the filter. Using a soft-lead pencil, mark the position(s) of the band(s) of interest. Cut out strips of nitrocellulose filter that carry the target antigen.

8. Arrange the nitrocellulose strips on pieces of Parafilm that are pressed onto the bottoms of petri dishes. Add a small volume of elution buffer to each strip (200–500  $\mu$ l, depending on the width of the strip). Incubate the strips on a rocking platform in a humidified atmosphere for 20 minutes at room temperature.

The Parafilm prevents the elution buffer from spreading over the surface of the dish. A typical humidified tissue culture incubator set at room temperature provides an adequate moist atmosphere.



9. Transfer the eluted antibody to a microfuge tube. Neutralize the elution buffer as soon as possible by adding 0.1 volume of 1 M Tris base. Check that the pH is near neutrality by spotting an aliquot of the solution on pH paper.

10. Add 0.1 volume of  $10 \times$  PBS. Add sodium azide to a final concentration of 0.02%, and store the antibody at  $4^{\circ}\text{C}$ .

#### Notes

- i. The strip of nitrocellulose can be used several times in succession to purify antibody specific for the immobilized antigen. However, the strip should not be allowed to dry between successive rounds of purification and must be retreated with blocking buffer after each round of elution.
- ii. Antibodies of the appropriate subclass purified in this way may be concentrated by adsorption to, and elution from, protein A–Sephadex.

## Immunological Assays

Antibodies are used in a wide variety of assays, both qualitative and quantitative, to detect and measure the amount of target antigens. These assays include immunoprecipitation, western blotting, and solid-phase radioimmunoassays (RIAs), which will be described in detail in the remainder of this chapter.

### SOLID-PHASE RADIOIMMUNOASSAY

The solid-phase RIA is a quantitative method that is capable of detecting as little as 1 pg of target antigen. This means that RIAs are sufficiently sensitive to measure, for example, the amount of foreign protein produced by transfected mammalian cell cultures. There are many different kinds of RIAs, which fall into four basic designs:

- **Competition RIAs:** In this method, the unlabeled target protein in the test sample competes with a constant amount of radiolabeled protein for binding sites on the antibody. The amount of radioactivity present in the unbound or bound target protein is then measured. This type of assay can be extremely sensitive but requires that target protein is available (preferably in a pure form) to serve both as a competitor and as a standard.
- **Immobilized antigen RIAs:** In this method, unlabeled antigen is attached to a solid support and exposed to radiolabeled antibody. Comparison of the amount of radioactivity that binds specifically to the samples under test with the amount that binds to a known amount of immobilized antigen allows the antigen in the test samples to be quantitated. Although used occasionally, this type of assay is not particularly useful for quantitation of small amounts of foreign protein in complex mixtures (e.g., in cell lysates); most of the binding sites on the solid support become occupied by proteins other than the target protein, so that the sensitivity of the assay is comparatively low.
- **Immobilized antibody RIAs:** In this method, a single antibody bound to a solid support is exposed to radiolabeled antigen. The amount of antigen in the test sample can be determined by the amount of radioactivity that binds to the antibody. This assay is not useful for quantitating the amount of foreign protein in many different samples, chiefly because of the practical difficulty of radiolabeling the protein either in vivo or in vitro.
- **Double-antibody RIAs:** In this method, one antibody bound to a solid support is exposed to the unlabeled target protein. After washing, the target protein bound to the immobilized antibody is quantitated with an excess of a second radiolabeled antibody. This assay is extremely sensitive and specific because the target protein is essentially purified and concentrated by immunoadsorption. Furthermore, many test samples can be processed simultaneously. However, the method requires that the first and

second antibodies recognize nonoverlapping epitopes on the target protein. Ideally, the first antibody is monoclonal, whereas the second can be either a polyclonal antibody or a monoclonal antibody of different specificity. However, in some cases, it may be possible to use the same polyclonal antibody for both parts of the assay. If suitable antibodies are available, this is the method of choice for quantitation of target proteins in complex mixtures.




FIGURE 18.1

### Solid-phase Radioimmunoassays Using Two Antibodies

The main features that affect the quality of the results obtained with RIAs are the sensitivity, accuracy, and specificity of the assay. The sensitivity of the assay is determined by two factors:

- The amount of the first antibody that is bound to the solid support (usually a 96-well polyvinyl chloride (PVC) plate). There are a finite number of binding sites on the surface of the solid support and, at saturation, each well of the plate binds approximately 100 ng of pure IgG ( $\sim 6 \times 10^{11}$  molecules). However, antibodies directed against the target protein must compete with immunoglobulins and other components in the serum for binding sites on the solid support. To maximize binding of relevant antibodies, immunoglobulins directed against the target protein should first be purified by immunoaffinity chromatography. Frequently, however, excellent results may be obtained using immunoglobulins purified from hyperimmune sera either by adsorption to, and elution from, protein A-Sepharose or by chromatography on DEAE-cellulose.
- The specific activity of the second radiolabeled antibody. Antibodies radiolabeled with  $^{125}\text{I}$  as described later in this chapter (see pages 18.24–18.25) have an approximate specific activity of  $5 \times 10^6$  cpm/ $\mu\text{g}$ . The amount of the radiolabeled second antibody that reacts with antigen-antibody complexes bound to a solid support varies from antigen to antigen. Typically, however, a saturating amount of protein antigen attached to an immobilized first antibody might be expected to bind approximately  $2 \times 10^4$ – $1 \times 10^5$  cpm of radiolabeled second antibody per well.

The accuracy of the assay is determined by the concentration of antigen in solution, which should not be so high as to saturate the antibody bound to the solid support. Quantitative results can be obtained only when the amount of antigen bound to the first antibody is proportional to its concentration in the sample being tested. To compare the amount of antigen in a number of test samples, assay several different dilutions of each sample (blocking buffer should be used as a diluent). Plot the amount of radioactive second antibody bound to each well against the dilution of the sample. Within the linear range of the assay (see Figure 18.1), there is a proportional relationship between the amount of radioactivity that is specifically bound and the dilution of antigen. In some cases, it may be possible to calculate the absolute amount of antigen present in a test sample from a standard curve obtained using known amounts of pure antigen. If a standard curve with known amounts of pure antigen is not available, the relative amounts of antigen in different samples may be estimated by calculating the dilution of antigen that will give half-maximal binding of radiolabeled antibody. In this case, it is essential that the dilutions span a wide range from background to maximal binding. For accurate quantitation of antigen, it is essential that the radiolabeled second antibody be present in excess. The appropriate amount of second antibody should be determined in pilot experiments in which different amounts of radiolabeled antibody are added to saturating amounts of bound antigen-antibody complexes.

The specificity of the assay is determined chiefly by the quality of the antisera used. However, even when monoclonal antibodies or immuno-

globulins purified from hyperimmune sera are used, there is always the chance of immunological cross-reactions. For this reason, it is essential to include the appropriate controls every time a solid-phase RIA is carried out. For example, when measuring the amount of a foreign protein synthesized by a transfected culture of mammalian cells, it is necessary to use extracts of mock-transfected cells as negative controls. Other essential controls include:

- *Immunoglobulins purified from preimmune serum*, which should be used in some wells in place of antibodies directed against the target antigen. If a monoclonal antibody is used as the first antibody, use a monoclonal antibody directed against an irrelevant antigen as a control. The amount of radiolabeled antibody that binds to wells treated with preimmune immunoglobulin and saturating amounts of antigen should be at least tenfold lower than the amount that binds to wells exposed to immune immunoglobulin and antigen. If the immune serum is highly specific, the signal-to-noise ratio can be as high as 100:1 in solid-phase RIAs.
- *Blank wells*, which are exposed to phosphate-buffered saline (PBS; see Appendix B) instead of first antibody. The blank wells are then exposed to blocking buffer and radiolabeled second antibody as described below. If blocking is complete, negligible amounts of radiolabeled second antibody should bind to the blank wells.

- *Positive wells*, which are exposed to known quantities of antigen.

A generalized protocol for a solid-phase RIA is given below.

1. Plan the experiment, and draw a key so that you will know what each well on the plate contains.
2. To each well of a PVC plate, add 50  $\mu$ l of IgG solution (20  $\mu$ g/ml in 0.2 M  $\text{NaHCO}_3$ ). Cover the plate, and incubate it for 2 hours at room temperature in a humidified atmosphere.

A typical humidified tissue culture incubator set at room temperature provides an adequate moist atmosphere.

The covers supplied with the plates fit very loosely, and incubation in a humidified atmosphere is necessary to prevent drying of the samples at the edges of the plates. An alternative way to deal with this problem is to purchase plates without covers (which are less expensive) and to wrap them tightly in Saran Wrap. The plates can then be incubated in the open on the bench.

3. Aspirate the IgG solution from the wells. The solution may be saved, stored at 4°C, and reused several times.

**Important:** Do not let the wells become dry at any stage during the remainder of the protocol.

4. Using a squirt bottle, wash the wells twice with blocking buffer. The IgG solution and the washes can be removed quickly and efficiently by flicking the plate over the sink or a suitable waste container.

### Blocking buffer

3% bovine serum albumin in PBS containing 0.02% sodium azide.

**Caution:** Sodium azide is poisonous. It should be handled with great care wearing gloves, and solutions containing it should be clearly marked.

5. Fill the wells with blocking buffer. Cover the plate and incubate it for 20 minutes at room temperature in a humidified atmosphere.

The bovine serum albumin serves as a blocking agent by binding to sites on the PVC plate that are not occupied by immunoglobulin molecules.

The antibody-coated plates may be stored for several days at 4°C if the wells are completely filled with blocking buffer. Before use, plates that have been stored in this fashion should be rinsed with blocking buffer.

6. Wash the wells twice more with blocking buffer (see step 4).
7. Make a series of dilutions in blocking buffer of the antigen that is to be assayed. Add 50  $\mu$ l of each dilution to each of two wells. Cover the plate and incubate it for 2 hours at room temperature in a humidified atmosphere or for 8 hours at 4°C.

8. Wash the plate four times with blocking buffer (see step 4).

9. Dilute the second antibody, radiolabeled with  $^{125}\text{I}$  as described on pages 18.24–18.25, in blocking buffer. To each well, add 50  $\mu$ l of radiolabeled antibody containing 50,000–200,000 cpm (5–20 ng). Cover the plate and incubate it for at least 2 hours at room temperature in a humidified atmosphere.

10. Wash the plate several times with blocking buffer. Quickly remove as much fluid as possible from each well by aspiration, using a Pasteur pipette attached to a vacuum line equipped with traps (see Appendix E, Figure E.1).

11. Using sharp scissors, cut individual wells from the plate. Place each well in a labeled counting vial, and measure the radioactivity in a gamma counter.

12. Plot the amount of radioactivity specifically bound to the test samples. Calculate the dilution of each sample that yields half-maximal binding of radiolabeled antibody. Calculate the amount of antigen present in each sample relative to the controls.

The amount of specifically bound radioactivity varies considerably from antigen to antigen and from antiserum to antiserum. However, it would be reasonable to expect 10 ng of purified, immobilized target antigen to bind between 1000 and 10,000 cpm of radiolabeled antibody.



## Iodination of Antibodies

Of the several methods that are available to radioiodinate antibodies, the most commonly used is a reaction in which  $\text{H}_2\text{O}^{125}\text{I}^+$ , generated by oxidation of  $\text{Na}^{125}\text{I}$  with chloramine-T, attacks the side chains of tyrosine residues and, to a lesser extent, histidine residues (Greenwood et al. 1963; McConahey and Dixon 1966, 1980). This modification, if not carried out to excess, generally does not affect the ability of the antibody to interact with its target antigen. However, in some cases (presumably when the antibody has a tyrosine residue in its antigen binding site), the immunoreactivity of radioiodinated antibody may be significantly reduced. It is then necessary to use a conjugation reagent such as Bolton-Hunter reagent (Bolton and Hunter 1973). The *N*-succinimidyl group of this reagent (*N*-succinimidyl 3-(4-hydroxy 5- $^{125}\text{I}$ iodophenyl)propionate) condenses with the free amino and imino in lysine and histidine residues to give a derivative in which the radioiodinated phenyl group is linked to an amide bond in the target protein. (For methods involving this reagent, see Langone 1980; Harlow and Lane 1988.)

**Caution:**  $^{125}\text{I}$  is a potential health hazard. It emits low-energy  $\gamma$ - and X-rays, is volatile, and accumulates in the thyroid. Under United States regulations, the maximum allowable load of  $^{125}\text{I}$  in the thyroid is 1.2  $\mu\text{Ci}$ . However, the procedures established by the local radiation safety committee, if strictly followed, should ensure that those working with  $^{125}\text{I}$  stay well within this limit.

## RADIOIODINATION OF ANTIBODIES USING THE CHLORAMINE-T METHOD

1. Equilibrate Sephadex G-25 in phosphate-buffered saline (PBS; see Appendix B) according to the manufacturer's instructions. Prepare a column in a Pasteur pipette that is plugged with sterile glass wool. Run at least 10 column volumes of PBS containing 1% bovine serum albumin through the column. Then wash the column with 5 volumes of PBS lacking bovine serum albumin. When the column is ready, wrap a piece of Parafilm around the bottom of the pipette. This prevents the column from running dry.

Prepared columns (PD-10 Sephadex G-25M) can be purchased from Pharmacia.

Pretreatment with bovine serum albumin reduces nonspecific adsorption of antibody to the column and resin. It is important to remove bovine serum albumin from the column buffer before applying the radioiodinated antibody; otherwise, there is a possibility that the bovine serum albumin in the solution will become radioiodinated.

2. In a microtuge tube, add up to 70  $\mu\text{g}$  of antibody (dissolved in 10  $\mu\text{l}$  of PBS) to 50  $\mu\text{l}$  of 50 mM sodium phosphate buffer (pH 7.2).

Since the radioiodination of proteins involves oxidation of radioiodide by chloramine-T, it is essential that no reducing agents be present in any of the solutions used.

**Caution:** The following steps must be carried out in a ventilated chemical hood behind shielding that is sufficient to protect the worker from direct radiation. Consult your radiation safety officer before beginning work with  $^{125}\text{I}$ , and make sure you are familiar with the procedures used to monitor and dispose of the radioisotope.

3. Add 500  $\mu\text{Ci}$  of carrier-free  $\text{Na}^{125}\text{I}$  and mix the solution well.

$\text{Na}^{125}\text{I}$  is usually supplied in 0.1 N NaOH, which minimizes oxidation. 50  $\mu\text{l}$  of sodium phosphate buffer can accommodate up to 7  $\mu\text{l}$  of 0.1 N NaOH without significant change in pH. However, the sudden addition of larger amounts of NaOH to the antibody can cause denaturation. This can be avoided by neutralizing the radioiodide solution with an equal volume of 0.1 N HCl just before use. Neutralized solutions of  $\text{Na}^{125}\text{I}$  must be used immediately to avoid loss of the volatile  $^{125}\text{I}$ . Carrier-free  $\text{Na}^{125}\text{I}$  should be used to minimize the total amount of iodine incorporated into the antibody.

4. Add 15  $\mu\text{l}$  of a freshly prepared solution of chloramine-T (2 mg/ml in 0.1 M sodium phosphate buffer [pH 7.2]).

5. Incubate the mixture for 60 seconds at room temperature.

6. Add 50  $\mu\text{l}$  of stop buffer, and immediately apply the mixture to the column of Sephadex G-25.

### Stop buffer

0.1 M sodium phosphate buffer (pH 7.2) containing  
10 mg/ml tyrosine  
2 mg/ml sodium metabisulfite  
10% glycerol  
0.1% xylene cyanol FF

7. Begin collecting 100–150- $\mu\text{l}$  fractions of the eluate from the column. After the sample has entered the resin, add PBS (lacking bovine serum albumin) to the top of the column. Make sure that the column does not run dry at any stage.

8. Using a hand-held minimonitor, check the radioactivity that elutes from the column. If the reaction has gone well, approximately 90% of the radiolabel should be incorporated into the antibody. The radiolabeled antibody should elute well ahead of the xylene cyanol FF, which runs with the unincorporated radiolabel. When the antibody has eluted, seal the bottom of the pipette with modeling clay. Dispose of the entire column, which still contains unincorporated radiolabel, in the radioactive waste.

9. Combine the fractions containing the radiolabeled antibody. Add bovine serum albumin to a final concentration of 1%. Measure the radioactivity in a 5- $\mu\text{l}$  aliquot, and store the antibody at 4°C until it is required for use.

If the immunoreactivity of the antibody is reduced by the above procedure, test the effects of metabisulfite on the protein. If metabisulfite damages the protein, omit it from the stop buffer. If, as is most likely, the antibody is insensitive to metabisulfite, the reduction in immunoreactivity must be caused by exposure to chloramine-T or to the incorporation of iodine into sensitive tyrosine residues. In either case, it will be necessary to try another method of radioiodination, for example, Bolton-Hunter reagent (Langone 1980; Harlow and Lane 1988).

The specific activity of the radiolabeled antibody should be  $\sim 5 \times 10^4$  cpm/ $\mu\text{g}$ .

## **TRANSFER OF PROTEINS FROM SDS-POLYACRYLAMIDE GELS TO SOLID SUPPORTS: IMMUNOLOGICAL DETECTION OF IMMOBILIZED PROTEINS (WESTERN BLOTTING)**

Western blotting (Towbin et al. 1979; Burnette 1981) is to proteins what Southern blotting is to DNA. In both techniques, electrophoretically separated components are transferred from a gel to a solid support and probed with reagents that are specific for particular sequences of amino acids (western blotting) or nucleotides (Southern hybridization). In the case of proteins, the probes usually are antibodies that react specifically with antigenic epitopes displayed by the target protein attached to the solid support. Western blotting is therefore extremely useful for the identification and quantitation of specific proteins in complex mixtures of proteins that are not radiolabeled. The technique is almost as sensitive as standard solid-phase radioimmunoassays and, unlike immunoprecipitation, does not require that the target protein be radiolabeled. Furthermore, because electrophoretic separation of proteins is almost always carried out under denaturing conditions, any problems of solubilization, aggregation, and coprecipitation of the target protein with adventitious proteins are eliminated.

The critical difference between Southern and western blotting lies in the nature of the probes. Whereas nucleic acid probes hybridize with a specificity and rate that can be predicted by simple equations (see Chapter 10), antibodies behave in a much more idiosyncratic manner. As discussed earlier in this chapter, an individual immunoglobulin may preferentially recognize a particular conformation of its target epitope (e.g., denatured or native). Consequently, not all monoclonal antibodies are suitable for use as probes in western blots, where the target proteins are thoroughly denatured. Polyclonal antisera, on the other hand, are undefined mixtures of individual immunoglobulins, whose specificity, affinity, and concentration are often unknown. Consequently, it is not possible to predict the efficiency with which a given polyclonal antiserum will detect different antigenic epitopes of an immobilized, denatured target protein.

Although there is an obvious danger that comes from using undefined reagents to assay a target protein that may also be poorly characterized, most problems that arise with western blotting in practice can be solved by designing adequate controls. These include the use of (1) antibodies (i.e., preimmune sera or irrelevant monoclonal antibodies) that should not react with the target protein and (2) control preparations that either contain known amounts of target antigen or lack it altogether.

Often, there is little choice of immunological reagents for western blotting—it is simply necessary to work with whatever antibodies are at hand. However, if a choice is available, either a high-titer polyclonal antiserum or a mixture of monoclonal antibodies raised against the denatured protein should be used. Reliance on a single monoclonal antibody is hazardous because of the high frequency of spurious cross-reactions with irrelevant proteins. If, as is usually the case, monoclonal and polyclonal antibodies have been raised against native target protein, it will be necessary to verify that they react with epitopes that either (1) resist denaturation with SDS and reducing agents or (2) are created by such treatment. This can be



done by using denatured target antigen in a solid-phase radioimmunoassay (see pages 18.19–18.23) or in western dot blots.

In western blotting, the samples to be assayed are solubilized with detergents and reducing agents, separated by SDS-polyacrylamide gel electrophoresis, and transferred to a solid support (usually a nitrocellulose filter), which may then be stained. The filter is subsequently exposed to unlabeled antibodies specific for the target protein. Finally, the bound antibody is detected by one of several secondary immunological reagents ( $^{125}\text{I}$ -labeled protein A or anti-immunoglobulin, or anti-immunoglobulin or protein A coupled to horseradish peroxidase or alkaline phosphatase). As little as 1–5 ng of an average-sized protein can be detected by western blotting.

### ***Preparation and Electrophoresis of Samples***

Two methods are used to extract proteins for western blotting from cells: Either the intact cells are dissolved directly in sample buffer or an extract is made as described earlier for samples to be immunoprecipitated (see pages 18.30–18.41). Which of these methods is best in any individual case depends on the type of cells and on the properties of the antigen.

- In general, bacteria expressing the target protein are lysed directly in SDS gel-loading buffer as described on pages 18.40–18.41.
- Yeasts are first lysed by vortexing in the presence of glass beads or enzymatically (see pages 18.35–18.36), and the resulting extracts are then prepared (see pages 18.35–18.39).
- Mammalian tissues are usually dispersed mechanically and then dissolved directly in SDS gel-loading buffer.
- Mammalian cells in tissue culture may be lysed gently with detergents as described on page 18.34, or, alternatively, the protocol on pages 18.62–18.63, in which the cells are lysed directly in SDS gel-loading buffer, may be used if the target antigen is resistant to this type of extraction.

In any case, the samples are analyzed by SDS-polyacrylamide gel electrophoresis as described on pages 18.47–18.54.

# BIOCHEMISTRY

THIRD EDITION

*Lubert Stryer*

LUBERT STRYER  
STANFORD UNIVERSITY



W. H. FREEMAN AND COMPANY / NEW YORK

EXHIBIT C

*To my teachers*

*Paul F. Brandwein  
Daniel L. Harris  
Douglas E. Smith  
Elkan R. Blout  
Edward M. Purcell*

Library of Congress Cataloging-in-Publication Data

Stryer, Lubert.  
Biochemistry.

Includes index.

1. Biochemistry. I. Title.

QP514.2.S66 1988 574.192 87-36486

ISBN 0-7167-1843-X

ISBN 0-7167-1920-7 (international student ed.)

Copyright © 1975, 1981, 1988 by Lubert Stryer

No part of this book may be reproduced by any mechanical, photographic, or electronic process, or in the form of a phonographic recording, nor may it be stored in a retrieval system, transmitted, or otherwise copied for public or private use, without written permission from the publisher.

Printed in the United States of America

234567890 RRD 654321098

# Contents

List of Topics	ix
Preface to the Third Edition	xxv
Preface to the Second Edition	xxix
Preface to the First Edition	xxx

---

## PART I MOLECULAR DESIGN OF LIFE I

---

CHAPTER 1.	Prelude	3
2.	Protein Structure and Function	15
3.	Exploring Proteins	43
4.	DNA and RNA: Molecules of Heredity	71
5.	Flow of Genetic Information	91
6.	Exploring Genes: Analyzing, Constructing, and Cloning DNA	117

---

## PART II PROTEIN CONFORMATION, DYNAMICS, AND FUNCTION 141

---

CHAPTER 7.	Oxygen-transporting Proteins: Myoglobin and Hemoglobin	143
8.	Introduction to Enzymes	177
9.	Mechanisms of Enzyme Action	201
10.	Control of Enzymatic Activity	233
11.	Connective-Tissue Proteins	261
12.	Introduction to Biological Membranes	283

### PART III GENERATION AND STORAGE OF METABOLIC ENERGY 313

- CHAPTER 13. Metabolism: Basic Concepts and Design 315  
 14. Carbohydrates 331  
 15. Glycolysis 349  
 16. Citric Acid Cycle 373  
 17. Oxidative Phosphorylation 397  
 18. Pentose Phosphate Pathway and Gluconeogenesis 427  
 19. Glycogen Metabolism 449  
 20. Fatty Acid Metabolism 469  
 21. Amino Acid Degradation and the Urea Cycle 495  
 22. Photosynthesis 517

### PART IV BIOSYNTHESIS OF MACROMOLECULAR PRECURSORS 545

- CHAPTER 23. Biosynthesis of Membrane Lipids and Steroid Hormones 547  
 24. Biosynthesis of Amino Acids and Heme 575  
 25. Biosynthesis of Nucleotides 601  
 26. Integration of Metabolism 627

### PART V GENETIC INFORMATION: storage, transmission, and expression 647

- CHAPTER 27. DNA Structure, Replication, and Repair 649  
 28. Gene Rearrangements: Recombination and Transposition 687  
 29. RNA Synthesis and Splicing 703  
 30. Protein Synthesis 733  
 31. Protein Targeting 767  
 32. Control of Gene Expression in Prokaryotes 799  
 33. Eucaryotic Chromosomes and Gene Expression 823  
 34. Viruses and Oncogenes 851

### PART VI MOLECULAR PHYSIOLOGY: interaction of information, conformation, and metabolism in physiological processes 887

- CHAPTER 35. Molecular Immunology 889  
 36. Muscle Contraction and Cell Motility 921  
 37. Membrane Transport 949  
 38. Hormone Action 975  
 39. Excitable Membranes and Sensory Systems 1005  
 Appendixes 1044  
 Answers to Problems 1049  
 Index 1065

## List of Topics

Proteins have unique amino acid sequences that are specified by genes 23  
 Protein modification and cleavage confer new capabilities 24

The peptide unit is rigid and planar 25

Polypeptide chains can fold into regular structures: the  $\alpha$  helix and  $\beta$  pleated sheets 25

Polypeptide chains can reverse direction by making  $\beta$ -turns 28

Proteins are rich in hydrogen-bonding potentiality 28

Water-soluble proteins fold into compact structures with nonpolar cores 29

Levels of structure in protein architecture 31

Amino acid sequence specifies three-dimensional structure 32

Proteins fold by the association of  $\alpha$ -helical and  $\beta$ -strand segments 34

Prediction of conformation from amino acid sequence 35

Essence of protein action: specific binding and transmission of conformational changes 37

Appendix: Acid-base concepts 41

#### CHAPTER 3 Exploring Proteins 43

Proteins can be separated by gel electrophoresis and displayed 44

Proteins can be purified according to size, charge, and binding affinity 46

Ultracentrifugation is valuable for separating biomolecules and determining molecular weights 49

Amino acid sequences can be determined by automated Edman degradation 50

Proteins can be specifically cleaved into small peptides to facilitate analysis 55

#### PART I MOLECULAR DESIGN OF LIFE 1



#### CHAPTER 1 Prelude 3

Molecular models depict three-dimensional structure 4  
 Space, time, and energy 5

Reversible interactions of biomolecules are mediated by three kinds of noncovalent bonds 7

The biologically important properties of water are its polarity and cohesiveness 9

Water solvates polar molecules and weakens ionic and hydrogen bonds 9

Hydrophobic interactions: nonpolar groups tend to associate in water 10

Design of this book 11

#### CHAPTER 2 Protein Structure and Function 15

Proteins are built from a repertoire of twenty amino acids 16

Amino acids are linked by peptide bonds to form polypeptide chains 22

charged terminal amino group of the peptide to form a phenylthiocarbonyl derivative. Then, under mildly acidic conditions, a cyclic derivative of the terminal amino acid is liberated, which leaves an intact peptide shortened by one amino acid. The cyclic compound is a phenylthiohydantoin (PTH) amino acid, which can be identified by chromatographic procedures. Furthermore, the amino acid composition of the shortened peptide:

(Arg, Asp, Gly, Phe)

can be compared with that of the original peptide:


(Ala, Arg, Asp, Gly, Phe)

The difference between these analyses is one alanine residue, which shows that alanine is the amino-terminal residue of the original peptide. The Edman procedure can then be repeated on the shortened peptide. The amino acid analysis after the second round of degradation is

(Arg, Asp, Gly, Phe)

showing that the second residue from the amino end is glycine. This conclusion can be confirmed by chromatographic identification of PTH-glycine obtained in the second round of the Edman degradation. Three more rounds of the Edman degradation will reveal the complete sequence of the original peptide.

Analyses of protein structures have been markedly accelerated by the development of *sequenators*, which are automated instruments for the determination of amino acid sequence. In a liquid-phase sequenator, a thin film of protein in a spinning cylindrical cup is subjected to the Edman degradation. The reagents and extracting solvents are passed over the immobilized film of protein, and the released PTH-amino acid is identified by high-performance liquid chromatography (HPLC; Figure 3-19). One cycle of the Edman degradation is carried out in less




**Figure 3-19**  
PTH-amino acids can be rapidly separated by high-pressure liquid chromatography (HPLC). In this HPLC profile, a mixture of PTH-amino acids is clearly resolved into its components. An individual amino acid can be identified by comparing its profile with this one.

than two hours. By repeated degradations, the amino acid sequence of some fifty residues in a protein can be determined. A recently devised gas-phase sequenator can analyze picomole quantities of peptides and proteins. This high sensitivity makes it feasible to analyze the sequence of a protein sample eluted from a single band of an SDS-polyacrylamide gel.


### PROTEINS CAN BE SPECIFICALLY CLEAVED INTO SMALL PEPTIDES TO FACILITATE ANALYSIS

Peptides much longer than about fifty residues cannot be reliably sequenced by the Edman method because not quite all peptides in the reaction mixture release the amino acid derivative at each step. If the efficiency of release of each round were 98%, the proportion of "correct" amino acid released after sixty rounds would be only 0.3 (0.98<sup>60</sup>)—a hopelessly impure mix. This obstacle can be circumvented by specifically cleaving a protein into peptides not much longer than fifty residues. In essence, the strategy is to divide and conquer.

Specific cleavage can be achieved by chemical or enzymatic methods. For example, Bernhard Witkop and Erhard Gross discovered that *cyanogen bromide* (CNBr) splits polypeptide chains only on the carboxyl side of methionine residues (Figure 3-20). A protein that has ten methionines will usually yield eleven peptides on cleavage with CNBr. Highly specific cleavage is also obtained with trypsin, a proteolytic enzyme from pancreatic juice. Trypsin cleaves polypeptide chains on the carboxyl side of arginine and lysine residues (Figure 3-21). A protein




**Figure 3-20**  
Cyanogen bromide cleaves polypeptides on the carboxyl side of methionine residues.



**Figure 3-21**  
Trypsin hydrolyzes polypeptide on the carboxyl side of arginine and lysine residues.






**Figure 3-33**  
(A) Electron micrograph of Polio virus. (B) Model based on x-ray crystallographic analysis. [Part A courtesy of Dr. T. W. Jeng and Dr. Wah Chiu. Part B (computer model and photograph) courtesy of Dr. Arthur J. Olson, Research Institute of Scripps Clinic. © 1987.]

The structures of more than 200 proteins have been elucidated at atomic resolution. Knowledge of their detailed molecular architecture has provided insight into how proteins recognize and bind other molecules, how they function as enzymes, how they fold, and how they evolved. This extraordinarily rich harvest is continuing at a rapid pace and profoundly influencing the entire field of biochemistry. Moreover, x-ray crystallography is being complemented by nuclear magnetic resonance (NMR) spectroscopy, electron microscopy, and electron crystallography, in obtaining increasingly informative views of biomolecules at high resolution. We shall be looking at the three-dimensional structures of proteins and other biomolecules throughout this book and relating the architecture of these molecules to their biological function.

### PROTEINS CAN BE QUANTITATED AND LOCALIZED BY HIGHLY SPECIFIC ANTIBODIES

An *antibody* is a protein synthesized by an animal in response to the presence of a foreign substance, called an *antigen* (Chapter 35). Antibodies (also called *immunoglobulins*) have specific affinity for the antigens that elicited their synthesis. Proteins, polysaccharides, and nucleic acids are effective antigens. Antibodies can also be formed to small molecules, such as synthetic peptides, provided that the small molecules are attached to a macromolecular carrier. The group recognized by an antibody is called an *antigenic determinant* (or *epitope*). Animals have a very large repertoire of antibody-producing cells, each producing antibody of a single specificity. An antigen acts by stimulating the proliferation of the small number of cells that were already forming complementary antibody. The major type of antibody in blood plasma is *immunoglobulin G*, a 150-kd protein containing two identical sites for the binding of antigen (Figure 3-34).

Antibodies that recognize a particular protein can be obtained by injecting the protein into a rabbit twice, three weeks apart. Blood is drawn from the immunized rabbit several weeks later and centrifuged. The resulting serum, called an *antisera*, usually contains the desired antibody. The antiserum or its immunoglobulin G fraction can be used




**Figure 3-34**  
Diagram of immunoglobulin G (IgG), the major class of antibody molecules in blood plasma. IgG contains two antigen-binding  $F_{ab}$  units and an  $F_c$  unit that mediates effector functions such as the lysis of cell membranes.


directly. Alternatively, antibody molecules specific for the antigen can be purified by affinity chromatography. Antibodies produced in this way are *polyclonal*—that is, they are products of many different populations of antibody-producing cells and hence differ somewhat in their precise specificity and affinity for the antigen. A major advance of recent years is the discovery of a means of producing *monoclonal antibodies* of virtually any desired specificity (p. 896). Monoclonal antibodies, in contrast with polyclonal ones, are homogeneous because they are synthesized by a population of identical cells (a clone). Each such population is descended from a single *hybridoma cell* formed by fusing an antibody-producing cell with a tumor cell that has the capacity for unlimited proliferation.

Closely related proteins can be distinguished by antibodies; indeed, a difference of just one residue on the surface can be detected. Antibodies can be used as exquisitely specific analytic reagents to quantitate the amount of a protein or other antigen. In a *solid-phase immunoassay*, antibody specific for a protein of interest is attached to a polymeric support such as a sheet of polyvinylchloride (Figure 3-35). A drop of cell extract or a sample of serum or urine is laid on the sheet, which is washed after formation of the antibody-antigen complex. Antibody specific for a different site on the antigen is then added, and the sheet is again washed. This second antibody carries a radioactive or fluorescent label so that it can be detected with high sensitivity. The amount of second antibody bound to the sheet is proportional to the quantity of antigen in the sample. The sensitivity of the assay can be enhanced even further if the second antibody is attached to an enzyme such as alkaline phosphatase. This enzyme can rapidly convert an added colorless substrate into a colored product, or a nonfluorescent substrate into an intensely fluorescent product (Figure 3-36). Less than a nanogram ( $10^{-9}$  g) of a protein can readily be measured by such an *enzyme-linked immunoassay* (ELISA), which is rapid and convenient. For example, pregnancy can be detected within a few days after conception by immunoassaying urine for the presence of human chorionic gonadotropin (hCG), a 37-kd protein hormone produced by the placenta.


Very small quantities of a protein of interest in a cell or in body fluid can be detected by an immunoassay technique called *Western blotting* (Figure 3-37). A sample is electrophoresed on an SDS polyacrylamide



**Figure 3-35**  
Solid-phase immunoassay. The steps are: coupling of specific antibody to a solid support, addition of the sample, washing to remove soluble components, and addition of a radiolabeled second antibody specific for a different site on the protein being detected.



**Figure 3-36**  
Enzyme-linked immunoassay (ELISA). The steps are the same as in the immunoassay described in Figure 3-35 except that an enzyme instead of a radiolabel is attached to the second antibody. An intensely colored or fluorescent compound is formed by the catalytic action of this enzyme.




**Figure 3-37**  
Detection of a protein on a gel by Western blotting. Proteins on an SDS-polyacrylamide gel are transferred to a polymer sheet and stained with radioactive antibody. A dark band corresponding to the protein of interest appears in the autoradiogram.

gel. The resolved proteins on the gel are transferred (by blotting) to a sheet to make them more accessible for reaction with a subsequently added antibody that is specific for the protein of interest. The antibody-antigen complex on the sheet then can be detected by rinsing the sheet with a second antibody specific for the first (e.g., goat antibody that recognizes mouse antibody). A radioactive label on the second antibody produces a dark band on x-ray film (an autoradiogram). Alternatively, an enzyme on the second antibody generates a colored product, as in the ELISA method. Western blotting makes it possible to find a protein in a complex mixture, the proverbial needle in a haystack. This technique is used advantageously in the cloning of genes (p. 133).

Antibodies are also valuable in determining the spatial distribution of antigens. Cells can be stained with fluorescent-labeled antibodies and examined by *fluorescence microscopy* to reveal the localization of a protein of interest. For example, arrays of parallel bundles are evident in cells stained with antibody specific for actin, a protein that polymerizes into filaments (Figure 3-38). Actin filaments are constituents of the cytoskel-


**Figure 3-38**

Fluorescence micrograph of actin filaments in a cell stained with an antibody specific to actin. [Courtesy of Dr. Elias Lazarides.]



**Figure 3-39**

The opaque 150 Å (15 nm) diameter particles in this electron micrograph are clusters of gold atoms bound to antibody molecules. These membrane vesicles from the synapses of neurons contain a channel protein that is recognized by the specific antibody. [Courtesy of Dr. Peter Sargent.]





eton, the internal scaffold of cells that controls their shape and movement. The finest resolution of fluorescence microscopy is about 0.2  $\mu\text{m}$  (200 nm or 2000 Å) because of the wavelength of visible light. Finer spatial resolution can be achieved by electron microscopy using antibodies tagged with electron-dense markers. For example, ferritin conjugated to an antibody can readily be visualized by electron microscopy because it contains an electron-dense core of iron hydroxide. Clusters of gold can also be conjugated to antibodies to make them highly visible under the electron microscope. *Immunoelectron microscopy* can define the position of antigens to a resolution of 10 nm (100 Å) or finer (Figure 3-39).

### PEPTIDES CAN BE SYNTHESIZED BY AUTOMATED SOLID-PHASE METHODS



Synthesizing peptides of defined sequence is important for several reasons. First, *synthetic peptides can reveal the rules governing the three-dimensional conformation of proteins*. We can ask whether a particular sequence

by itself folds into an  $\alpha$ -helix,  $\beta$ -strand, or hairpin turn or behaves as a random coil. Second, *many hormones and other signal molecules in nature are peptides*. For example, white blood cells are attracted to bacteria by formylmethionyl peptides that come from the breakdown of bacterial proteins. Synthetic formyl-methionyl peptides have been useful in identifying the cell-surface receptor for this class of peptides. Synthetic peptides can be attached to agarose beads to prepare affinity chromatography columns for the purification of receptor proteins that specifically recognize the peptides. Third, *synthetic peptides can serve as drugs*. Vasopressin is a peptide hormone that stimulates the reabsorption of water in the distal tubules of the kidney, leading to the formation of a more concentrated urine. Patients with diabetes insipidus are deficient in vasopressin (also called antidiuretic hormone), and so they excrete large volumes of urine (more than 5 liters per day) and are continually thirsty because of this massive loss of fluid. This defect can be treated by administering 1-desamino-8-D-arginine vasopressin, a synthetic analog of the missing hormone (Figure 3-40). This synthetic peptide is degraded in vivo much more slowly than vasopressin and, additionally, does not increase the blood pressure. Fourth, *synthetic peptides can serve as antigens to stimulate the formation of specific antibodies*.



**Figure 3-40**  
Structural formulas of (A) vasopressin (also called antidiuretic hormone), a peptide hormone that stimulates water resorption, and (B) 1-desamino-8-D-arginine vasopressin, a more stable synthetic analog.

Peptides are synthesized by linking an amino group to a carboxyl group that has been activated by reacting it with a reagent such as *dicyclohexylcarbodiimide* (DCC) (Figure 3-41). The attack of a free amino group on the activated carboxyl leads to the formation of a peptide bond and the release of dicyclohexylurea. A unique product is formed only if a single amino group and a single carboxyl group are available for reaction. Hence, it is necessary to *block* (protect) all other potentially reactive groups. For example, the  $\alpha$ -amino group of the component containing the activated carboxyl group can be blocked with a *tert*-butoxycarbonyl (*t*-Boc) group. This *t*-Boc protecting group can be subsequently removed by exposing the peptide to dilute acid, which leaves peptide bonds intact.



**Figure 3-41**  
Dicyclohexylcarbodiimide is used to activate carboxyl groups for the formation of peptide bonds.

uct. Additional amino acids are linked by the same sequence of reactions. At the end of the synthesis, the peptide is released from the beads by adding HF, which cleaves the carboxyl ester anchor without disrupting peptide bonds. Protecting groups on potentially reactive side chains, such as that of lysine, are also removed at this time. This cycle of reactions can readily be automated, which makes it feasible to routinely synthesize peptides containing about 50 residues in good yield and purity. In fact, Merrifield has synthesized interferons (155 residues) that have antiviral activity and ribonuclease (124 residues) that is catalytically active.


## SUMMARY

The purification of a protein is an essential step in elucidating its structure and function. Proteins can be separated from each other and from other molecules on the basis of such characteristics as size, solubility, charge, and binding affinity. SDS-polyacrylamide gel electrophoresis separates the polypeptide chains of proteins under denaturing conditions largely according to mass. Proteins can also be separated electrophoretically on the basis of net charge by isoelectric focusing in a pH gradient. Ultracentrifugation and gel-filtration chromatography resolves proteins according to size, whereas ion-exchange chromatography separates them mainly on the basis of net charge. The high affinity of many proteins for specific chemical groups is exploited in affinity chromatography, in which proteins bind to columns containing beads bearing covalently linked substrates, inhibitors, or other specifically recognized groups.

The amino acid composition of a protein can be determined by hydrolyzing it into its constituent amino acids in 6 N HCl at 110°C. The amino acids can be separated by ion-exchange chromatography and quantitated by reacting them with ninhydrin or fluorescamine. Amino acid sequences can be determined by Edman degradation, which removes one amino acid at a time from the amino end of a peptide. Phenylisothiocyanate reacts with the terminal amino group to form a phenylthiocarbonyl derivative, which cyclizes under mildly acidic conditions to give a phenylthiohydantoin (PTH)-amino acid and a peptide shortened by one residue. This PTH-amino acid is identified by high-performance liquid chromatography (HPLC). Automated repeated Edman degradations by a sequencer can analyze sequences of about fifty residues. Longer polypeptide chains are broken into shorter ones for analysis by specifically cleaving them with a reagent such as cyanogen bromide, which splits peptide bonds on the carboxyl side of methionine residues. Enzymes such as trypsin, which cleaves on the carboxyl side of lysine and arginine residues, are also very useful in splitting proteins. Recombinant DNA techniques have revolutionized amino acid sequencing. The nucleotide sequence of DNA molecules reveals the amino acid sequence of nascent proteins encoded by them but does not disclose posttranslational modifications. Amino acid sequences are rich in information concerning the kinship of proteins, their evolutionary relations, and diseases produced by mutations. Knowledge of a sequence provides valuable clues to conformation and function.

Polypeptide chains can be synthesized by automated solid-phase methods in which the carboxyl end of the growing chain is linked to an insoluble support. The  $\alpha$ -carboxyl group of the incoming amino acid is

Peptides can be readily synthesized by a solid-phase method devised by R. Bruce Merrifield. Amino acids are added stepwise to a growing peptide chain that is linked to an insoluble matrix, such as polystyrene beads. A major advantage of this solid-phase method is that the desired product at each stage is bound to beads that can be rapidly filtered and washed and so the need to purify intermediates is obviated. All of the reactions are carried out in a single vessel, which eliminates losses due to repeated transfers of products. The carboxyl-terminal amino acid of the desired peptide sequence is first anchored to the polystyrene beads (Figure 3-42). The *t*-Boc protecting group of this amino acid is then removed. The next amino acid (in the protected *t*-Boc form) is added together with dicyclohexylcarbodiimide, the coupling agent. After formation of the peptide bond, excess reagents and dicyclohexylurea are washed away, which leaves the beads with the desired dipeptide prod-



**Figure 3-42** Solid-phase peptide synthesis. The steps are (A) anchoring of the C-terminal amino acid to a resin on the surface of polystyrene beads, (B) deprotection of the amino group, (C) addition of the next amino acid (in the protected form) and dicyclohexylcarbodiimide (DCC), (D) steps (B) and (C) are repeated for each added amino acid. The beads are washed to remove excess reagents and unwanted products after each step. Finally, (D) the completed peptide is released from the resin.

activated by dicyclohexylcarbodiimide and joined to the  $\alpha$ -amino group of the growing chain. Synthetic peptides can serve as drugs and as antigens to stimulate the formation of specific antibodies. They also provide insight into relations between amino acid sequence and conformation.

Proteins can be detected and quantitated by highly specific antibodies. Enzyme-linked immunosorbent assays (ELISA) and Western blots of SDS-polyacrylamide gels are used extensively. Proteins can also be localized within cells by fluorescence microscopy and immunoelectron microscopy using labeled antibodies. X-ray crystallography has revealed the three-dimensional structures of more than a hundred proteins in atomic detail. Knowledge of molecular structure has provided insight into how proteins fold, recognize other molecules, and catalyze chemical reactions.

## SELECTED READINGS

### Where to start

- Moore, S., and Stein, W. H., 1973. Chemical structures of pancreatic ribonuclease and deoxyribonuclease. *Science* 180:458-464.
- Hunkapiller, M. W., and Hood, L. E., 1983. Protein sequence analysis: automated microsequencing. *Science* 219:650-659.
- Merrifield, R., 1986. Solid phase synthesis. *Science* 232:341-347.

### Books on protein chemistry

- Creighton, T. E., 1983. *Proteins: Structure and Molecular Properties*. W. H. Freeman.
- Cooper, T. G., 1977. *The Tools of Biochemistry*. Wiley. (A valuable guide to experimental methods in protein chemistry and in other areas of biochemistry. Principles of procedures are clearly presented.)
- Hirs, C. H. W., and Timasheff, S. N., (eds.), 1983. *Enzyme Structure, Part I. Methods in Enzymology*, vol. 91. Academic Press. [An excellent collection of authoritative articles on amino acid analysis, end-group methods, chemical and enzymatic cleavage, peptide separation, sequence analysis, chemical modification, and active-site labeling. Also see volumes 47-49 in this series.]
- Scopes, R., 1982. *Protein Purification: Principles and Practice*. Springer-Verlag.
- Langone, J. J., and Van Vunakis, H., 1983. *Immunological Techniques, Part A. Methods in Enzymology*, vol. 92. Academic Press.

### Physical chemistry of proteins

- Cantor, C. R., and Schimmel, P. R., 1980. *Biophysical Chemistry*. W. H. Freeman. [An outstanding exposition of fundamental principles and experimental methods. Part 2 discusses many of the techniques presented in this chapter.]

- Freifelder, D., 1982. *Physical Biochemistry: Applications to Biochemistry and Molecular Biology*. W. H. Freeman. [Contains a lucid discussion of ultracentrifugation.]

### Amino acid sequence determination

- Hunkapiller, M. W., Strickler, J. E., and Wilson, K. J., 1984. Contemporary methodology for protein structure determination. *Science* 226:304-311.
- Hewick, R. M., Hunkapiller, M. W., Hood, L. E., and Dreyer, W. J., 1981. A gas-liquid solid phase peptide and protein sequenator. *J. Biol. Chem.* 256:7990-7997.
- Konigsberg, W. H., and Steinman, H. M., 1977. Strategy and methods of sequence analysis. In Neurath, H., and Hill, R. L., (eds.), *The Proteins* (3rd ed.), vol. 3, pp. 1-178. Academic Press.
- Stein, S., and Udénfriend, S., 1984. A picomole protein and peptide chemistry: some applications to the opioid peptides. *Analyt. Chem.* 136:7-23.

### Sequence comparisons and molecular evolution

- Doolittle, R. F., 1981. Similar amino acid sequences: chance or common ancestry? *J. Mol. Biol.* 16:9-16.
- Lipman, D. J., and Pearson, W. R., 1983. Rapid and sensitive protein similarity searches. *Science* 227:1435-1441. [Description of an algorithm that searches for similarities between an amino acid sequence and a large database of previously determined sequences. This program can be run on a personal computer.]
- Wilson, A. C., 1985. The molecular basis of evolution. *Sci. Amer.* 253(4):164.

### X-ray crystallography and NMR spectroscopy

- Matthews, B. W., 1977. X-ray structure of proteins. In Neurath, H., and Hill, R. L., (eds.), *The Proteins* (3rd ed.), vol. 3, pp. 404-590. Academic Press.

- Holmes, K. C., and Blow, D. M., 1965. *The Use of X-ray Diffraction in the Study of Protein and Nucleic Acid Structure*. Wiley-Interscience.
- Glusker, J. P., and Trueblood, K. N., 1972. *Cystal Structure Analysis: A Primer*. Oxford University Press. [A lucid and concise introduction to x-ray crystallography in general.]

## PROBLEMS

1. The following reagents are often used in protein chemistry:

CNBr	Dabsyl chloride
Urea	6 N HCl
$\beta$ -Mercaptoethanol	Ninhydrin
Trypsin	Phenyl isothiocyanate
Performic acid	Chymotrypsin

Which one is the best suited for accomplishing each of the following tasks?

- (a) Determination of the amino acid sequence of a small peptide.
- (b) Identification of the amino-terminal residue of a peptide (of which you have less than  $10^{-7}$  g).
- (c) Reversible denaturation of a protein devoid of disulfide bonds. Which additional reagent would you need if disulfide bonds were present?
- (d) Hydrolysis of peptide bonds on the carboxyl side of aromatic residues.
- (e) Cleavage of peptide bonds on the carboxyl side of methionines.
- (f) Hydrolysis of peptide bonds on the carboxyl side of lysine and arginine residues.
2. What is the ratio of base to acid at pH 4, 5, 6, 7, and 8 for an acid with a  $pK$  of 6?

3. Anhydrous hydrazine has been used to cleave peptide bonds in proteins. What are the reaction products? How might this technique be used to identify the carboxyl-terminal amino acid?

4. The amino acid sequence of human adrenocorticotropin, a polypeptide hormone, is  
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Ile-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asp-Ala-Gly-Glu-Asp-Gln-Ser-Ala-Glu-Ala-Phe-Leu-Glu-Phe

- (a) What is the approximate net charge of this molecule at pH 7? Assume that its side chains have the  $pK$  values given in Table 2-1 (p. 21) and that the  $pK$ s of the terminal  $-\text{NH}_3^+$  and  $-\text{COOH}$  groups are 7.8 and 3.6, respectively.
- (b) How many peptides result from the treatment of the hormone with cyanogen bromide?

5. Ethylenimine reacts with cysteine side chains in pro-

- teins to form S-aminoethyl derivatives. The peptide bonds on the carboxyl side of these modified cysteine residues are susceptible to hydrolysis by trypsin. Why?
6. The absorbance  $A$  of a solution is defined as

$$A = \log_{10} (I_0/I)$$

in which  $I_0$  is the incident light intensity and  $I$  is the transmitted light intensity. The absorbance is related to the molar absorption coefficient (extinction coefficient)  $\epsilon$  (in  $\text{cm}^{-1} \text{M}^{-1}$ ), concentration  $c$  (in  $\text{M}$ ), and path length  $l$  (in  $\text{cm}$ ) by

$$A = \epsilon lc$$

The absorption coefficient of myoglobin at 580 nm is  $15,000 \text{ cm}^{-1} \text{M}^{-1}$ . What is the absorbance of a 1 mg/ml solution across a 1-cm path? What percentage of the incident light is transmitted by this solution?

7. Tropomyosin, a 93-kd muscle protein, sediments more slowly than does hemoglobin (65 kd). Their sedimentation coefficients are 2.6 and 4.31 S, respectively. Which structural feature of tropomyosin accounts for its slow sedimentation?

8. The relative electrophoretic mobilities of a 30-kd protein and a 92-kd protein used as standards on an SDS-polyacrylamide gel are 0.80 and 0.41, respectively. What is the apparent mass of a protein having a mobility of 0.62 on this gel?

9. The relative electrophoretic mobility of a protein on an SDS-polyacrylamide gel decreases from 0.67 to 0.64 on addition of 1 mM dithiothreitol. What is a likely reason for this shift?

10. The gene encoding a protein with a single disulfide bond undergoes a mutation that changes a serine residue into a cysteine residue. You want to find out whether the disulfide pairing in this mutant is the same as in the original protein. Propose an experiment to directly answer this question.

11. A synthetic polypeptide consisting of L-lysine residues is a random coil at pH 7 but becomes  $\alpha$  helical as the pH is raised above 10. Account for this pH-dependent conformational transition.

12. Predict the pH dependence of the helix-coil transition of poly-L-glutamate.

## **Exhibit D**

### **Flt4 Fragment Amino Acid Sequences With Stop/Start Sites Corresponding to Positions of Cyanogen Bromide Cleavage of Flt4 Receptor Tyrosine Kinase And Comprising At Least One Extracellular Domain Amino Acid**

**Peptide 1:** 2 -QRGAALCLRLWLCLGLLDGLVSGYSM - 27

**Peptide 2:** 28 -TPPTLNITEESHVIDTGDSLSISCRGQHPL  
EWA WPGAQEAPATGDKDSED TG VVRDCEGTDAR  
PYCKVLLLEHVHANDTGSYVCYKYIKARIEGTTA  
ASSYVFVRDFEQPFINKPDTLLVNRKDAM - 154

**Peptide 3:** 155 -WVPCLVSIPGLNVTLSQSSVLWPDGQ  
EVVWDDRRGM - 191

**Peptide 4:** 192 -LVSTPLLHDALYLQCETT WGDQDFLSN  
PFLVHITGNELYDIQLLPKRSLELLVGEKLVNCT  
VWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQ  
THTELSSILTIHNVSQHDLGSYVCKANNGIQRFRS  
TEVIVHENPFISVEWLKGPILEATAGDELVKLPVK  
LAAYPPPEFQWYKDGKALSGRHSPHALVLKEVTE  
ASTGTYTLALWNSAAGLRRNISLELVNVNPPQIHE  
KEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWR  
PWTPCKM - 468

**Peptide 5:** 469 -FAQRS LRRRQQQDLM - 483

**Peptide 6:** 484 -PQCRDWRAVTTQDAVNPIESLDTWTEF  
VEGKNKTVSKLVIQNANVSAM - 531

**Peptide 7:** 532 -YKCVVSNKVGQDERLIYFYVTTIPDGFT  
IESKPSEELLEGPVLLSCQADSYKYEHLRWYRLN  
LSTLHDAHGNPLLLDCKNVHLFATPLAASLEEVPG  
ARHATLSLSIPRVPEHEGHYVCEVQDRRSHDKHCH  
KKYLSVQALEAPRLTQNLTDLLVNVSDSLEM - 697

**Peptide 8:** 698 -QCLVGAHAPSIVWYKDERLLEEKSGVD  
LADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNS  
SASVVEGSEDKGSM - 774

**Peptide 9:** 775 -EIVILVGTGVIAVFFWVLLLLIFCNM - 800

ry Match 38.3%; Score 2762; DB 1; Length 1356;  
t Local Similarity 44.1%; Pred. No. 1.5e-175;  
ches 608; Conservative 203; Mismatches 480; Indels 88; Gaps 26;

**EXHIBIT E**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**